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Figure 1. Yeast cells with typical budding (blastoconidia) and pseudohyphae 
Figure 2. Yeasts stained with calcofluor white 
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Candidosis 
adapted from: 
Andreas Voss. Paul E. Verweij, Jacques F.G.M Meis 
submitted 
and 
Bart Jan Kullberg and Andreas Voss 
Nederlands Tijdschrift voor Geneeskunde, 1996;140:148-151 _ U 
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CD | The term candidosis (mostly named candidiasis in the USA) is used to refer to infections due to о 
о 
organisms belonging to the genus Candida. In addition to mucosal and cutaneous -< 
о 
infections, these opportunistic pathogens can cause deep-seated infections, which may be •< 
restricted to one organ or disseminate throughout the human host. g 
Ö 
η 
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Species of the genus Candida are anamorphic (asexual) yeasts classified as Fungi Imper- 3-
fecti. Most members of the genus are dimorphic, in the sense that they form round or oval 
yeast cells with typical budding (blastoconidia) or generate pseudohyphae (Figure ]). C. 
albicans can also form true hyphae, whereas С glabrafa (formerly Torulopsis glabrata) never 
forms hyphae or pseudohyphae. Despite the fact that the presence of hyphae in tissue has 
been frequently postulated to be associated with true infection or invasion, and the presence 
of budding as colonization, respectively, these criteria are not firmly established ,7i. 
Taking taxonomie changes into account, approximately 200 Candida species are known 10, 
of which about 10% are recognized to cause infections in humans (Table 1). So far, Candida 
albicans is the single, most common fungal species causing (nosocomial) infections. In 
National Nosocomial Infections Surveillance (NNIS) hospitals, C. albicans accounted for 76% 
of 24,227 Candida infections during 1980-1990 e. In the Netherlands, 73% of all Candida 
infections were shown to be caused by C. albicans (Table 2 ) 2I°. С tropicalis is the second 
most frequent Candida species to cause infections in humans and may even be 
predominately isolated among children with leukemia and bone marrow transplant patients 
106 221 
Introduction 
Table 1: Common and rare Candida species known to cause human infections 
Species Clinical manifestation 
Common 
C. albicans 
C. glabrata 
C. krusei 
C. parapsilosis 
C. tropicalis 
skin/nail infections, vaginitis, thrush, esophagitis, enteritis, cystitis, 
disseminated infections such as: arthritis, pyelonephritis, pneumonia, 
endocarditis, meningitis, brain abscess, candidemia, and chronic 
disseminated candidosis 
candidemia and systemic candidosis, urinary tract infections 
candidemia, endopthalmitis, diarrhea in infants no,i76 
candidemia, endocarditis, septic arthritis, and peritonitis especially 
associated with prosthetic or indwelling devices. Epidemic 
infections due to contaminated devices and solutions 20.90,232 
candidemia and systemic candidosis especially among leukemic 
patients and iv drug abusers 47.10n.221 
Rare 
С catenulata 
C. citerai 
С. dubliniensis 
С. guilliermondii 
С. haemulonii 
С. kefyr 
(syn. С pseudotropicalisì 
С. lipolytica 
С. lusitaniae 
С. norvegensis 
С. pulcherrìma 
С. rugosa 
С. utilis 
С. viswanathii 
С. zeylano'ides 
onychomycosis 
onychomycosis 3S 
oral candidosis in HIV-infected patients 2 0 8 
systemic candidosis, endocarditis In iv drug abusers 
candidemia, skin infections5 4 
systemic candidosis 
catheter-related candidemia 2 2 8 
candidemia and disseminated infections such as pneumonia and 
pyelonephritis M 
candidemia in patients after kidney transpantation l 2 6 
Invasive candidosis in the compromised host 152,230 
catheter-related candidemia ' 6 I 
single case of catheter-related candidemia 4 
meningitis '7 9 
candidemia, arthritis '5 Ш 1 
Chapter 1 
Table 2: Distribution of Candida species causing nosocomial infections in USA hospitals 
(1980 - 1990) and in the Netherlands (1989) 
Candida species 
С albicans 
C. non-albicans 
C. glabrata 
C. tropicalis 
С. parapsilosis 
С. krusei 
С. guilliermondii 
С. stellatoidea 
С. pseudotropicalis 
Unspecified Candida species 
*Barnerjee et al A ** Tan et al 
% of isolates (USA)* 
210 
69.3 
8.8 
6.4 
2.3 
<1 
<1 
<1 
<1 
12 
% of isolates (NL)** 
73 
9 
3 
<1 
<1 
--
-
<1 
13 
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Members of the genus Candida are common inhabitants of the human gastrointestinal, and 
genitourinary tract. Mucosal surfaces may be colonized with C. albicans in up to 80% of 
hospitalized patients and tends to be significantly lower (2-37%) in healthy Individuals ¿o·127. 
Despite the fact that mere isolation from these sites is no proof of infection, adherence and 
persistence of Candida spp. on mucosal surfaces is the initial step in the development of 
candidosis. The strongest adherence capability is consequently found In the most virulent 
species, C. albicans and C. tropicalis, the latter showing an especially high affinity for plastic 
polymers '20- '7 '. 
Candida spp. produce a variety of virulence factors, such as proteinases and lipases that 
assist invasion of host tissue, but in general a combination of host and organism factors, rather 
than a single virulence factor, seems to favor the development of diseases ,28. Infections are 
probably initiated by changes in the host defense that mutilate the host-pathogen 
equilibrium. Whereas infections of the skin and mucosa are mainly due to changes of 
hydration, pH, nutrient concentrations, or the microbial environment of the skin and mucosa, 
disseminated candidosis is usually associated with Insufficiencies in host defense that 
commonly occur in hospitalized cancer and Intensive care patients, receiving chemotherapy 
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and broad-spectrum antimicrobial treatment 98.і9і.і9в.2і 1.24a Furthermore, in patients with 
systemic infections, the phagocytic cell defense systems seems to be severely altered 37.97.99 
Additional determinants of candidal pathogenesis are listed in Table 3. 
Table 3: Pathogenetic determinants of Candida species 
• Adherence (mannoproteins) 
• Candidal load 
• Enzymes (lipase, proteinase) 
• Formation of true- and pseudohyphae 
• Impediment of host immune defense 
• Persorption 
• Phenotypic variability ("Switching") 
• Synergism with bacterial and viral pathogens 
a d a p t e d from 55,128,171 
Invasion of mucosal barriers and subsequent systemic infections may furthermore be related 
to the candidal load (magnitude of colonization), as shown by an "healthy" investigator who 
"consumed" a suspension with 1012 С albicans cells which lead to persorption with 
subsequent candidemia and a Lancet publication 82. 
Epidemiology 
Recently, a world-wide increase of mucocutaneous and deep-seated fungal infections was 
observed. The total number of fungal infection in hospitals participating in the NNIS-system 
(National Nosocomial Infections Surveillance System) increased from 6% in 1980 to 10.4% in 
1990 13. Nearly 80% of these infections were caused by Candida species. An increasing 
incidence was observed for all clinical manifestations including oropharyngeal infections, 
postoperative site infections, and urinary tract infections, but was especially dramatic for 
candidemia ,3. 
The rising incidence of Candida infections and candidemia can be attributed to a variety of 
(mostly) endogenous and exogenous factors. 
• Granulocytopenia is the most important risk factor for the development of systemic 
candidosis in patients with c a n c e r l 9 63. The improved and intensified treatment of patients 
with cancer induced significantly prolonged granulocytopenia, thereby increasing the 
chance of fungal infections. Damage of the oropharyngeal mucosa through the use of , 
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aggressive cytostatic drugs, such as cytarabine, facilitate Candida colonization and 
subsequent invasion ". 
The escalating use of broad-spectrum antibiotics in hematology- and intensive care 
patients has been described as an independent risk factor for the development of 
Candida infections 23.238. Especially orally administered antibiotics or those with high 
entero-hepatic circulation, will enhance proliferation of Candida species colonizing the 
gastrointestinal tract (Table 4). In parallel, increased colonization or infections with non-
albicans Candida species are associated with the use of azole antifungals 193,244 
Histamine (H2) antagonists presumably effect the gastric flora either by elevation of the 
gastric pH or changes of mucosal attachment, allowing for increased Candida 
Colonization 1 ?A.204_ 
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Table 4: Risk factors of systemic candidosis (according to multivariate analysis) 
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Age 
Azotemia 
Central venous catheters 
Chemotherapy 
Colonization 
Damaged mucosal barrier 
Graft versus host disease 
Hemodialysis 
Hyperglycemia 
Long-term use of broad-spectrum antibiotics 
Neutropenia 
Parenteral nutrition 
Steroids 
Surgery (multiple, extended, abdominal) 
adapted from 23,59,81,234,237 
Portal of entry The portal of entry depends on the individual patient's condition and 
probably specific site preference of certain Candida species. In patients with candidemia, 
intravenous lines were the single most common (39%) portal of entry 8 I . In general most 
candidemias were due to С albicans, but 38% of the Candida isolates from bloodstream 
infections originating from the gastrointestinal tract were C. tropicalis 8 I . In patients receiving 
parenteral hyperalimentation, fungemia was predominantly due to С parapsilosis " 7 6 7 . The 
role of iv devices is controversially discussed by different authors s9.75.1ro but given the high 
incidence of candidemia among patients with central venous catheters found by Curry and 
Quie 34, the fact that 50% of these individuals had invasive infection at autopsy, and the 
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results of other studies, using multivariant analysis2 3 2 3 8 we believe that central venous lines are 
an important risk factor for candidemia. 
Candida typing Since the first description of the two C. alb/cans serotypes by 
Hasenclever et al in 1961 і6 Candida strain typing has progressed through various phenotypic 
and genotypic approaches (Table 5). DNA based methods such as restriction enzyme 
analysis using conventional or pulsed-field gel electrophoresis 41,184,217.218,222.225 electrophoretic 
karyotyping 77.104.143.159.222, arbitrarily primed PCR fingerprinting 9 5 · 1 8 9 , and Southern hybridization 
analysis using midrepeat sequence probes 1 8 6 · 1 8 7 have been proven to be the most helpful 
and are presently used as diagnostic tools or are applied to population studies. At present, a 
16 combination of phenotypic markers such as antifungal susceptibilities or biochemical profiles 
and a DNA-based typing method, or (in the research setting) two different DNA-based 
m 
5; methods, should be used to characterize Candida strains for clinical and epidemiological 
Φ ("molecular epidemiology") purposes, respectively. Standardized methodologies and 
¡a optimal methods to analyze typing results are still lacking, but a recently founded European 
• < 
2. working group on epidemiological markers may solve these problems in the near future. 
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Table 5: Candida strain typing 
Phenotyping 
Genotyping 
serotyping 
morphotyplng 
resistotyping 
biotyping 
killer factor typing 
karyotyping 
restriction fragment length polymorphism 
Southern bloting 
Random amplified polymorphic DNA typing 
(66) 
(146) 
(229) 
(130) 
(151) 
(104) 
(184) 
(187) 
(214) 
Molecular epidemiology Molecular typing was used to evaluate the pathogenesis of 
endogenous Candida infections, as well as to prove exogenous transmission. 
Evaluating the sequence of Candida colonization and candidemia it was proven that in 
about 90% of the neutropenic patients 1 5 8 · 2 1 4 and in 75-80% of the non-neutropenic patients 2 2 2 
the subsequently infecting strains were identical with the previous colonizing isolate. 
Furthermore, most patients were shown to develop infections with their own distinct Candida 
strain, thereby confirming the concept of endogenous infection 112,137,140.158.222 o n the other 
hand, classical concepts of endogenous pathogenesis such as that of gastrointestinal 
colonization and recurrent vulvovaginitis may become questionable. Stein et al. 205 
Chapter 1 
demonstrated that vaginal and rectal Candida strains from the same women with recurrent 
vulvovaginitis were usually different, whereas sequential vaginal isolates were identical, 
therefore suggesting "relapse" instead of autoinfection. 
Although the majority of Candida infections are probably of endogenous origin, exogenous 
sources and cross-infection have been proven using molecular typing methods. Among 
others, pigeon guano, contaminated devices (syringes [re-]used for total parenteral nutrition), 
and contaminated lemon juice have been described as exogenous sources U 4 1 "2 . The first 
outbreak of candidemia due to cross-infections via hands was described using sero- and 
biotypmg, but later outbreaks were confirmed using DNA-based methods 1*25273941 
Diagnosis 1 
Since clinical manifestations of localized and deep-seeded candidosis are not specific for 
Candida species, a laboratory identification of this microorganism is essential to establish a 
definitive diagnosis. Standard approaches to laboratory diagnosis include: 
a) direct microscopy 
b) culture 
c) histopathology 
ad a) Direct microscopy of freshly obtained specimens provides information about the relative 
amount of Candida species and their morphologic features, and the cellular composition of the 
inflammatory response. Direct examination of specimens may provide a rapid diagnosis of 
involvement by Candida species. The detection of fungal elements in tissue biopsy specimens, 
such as liver biopsy, is of great importance, since culture of the same material often remains 
negative. Special fungal stains, including potassium hydroxide (KOH) and calcofluor white 
(Figure 2), are available to facilitate the detection of fungal elements. 
ad b) Candida species generally grow well on common mycological and bacteriological 
media, including Sabouraud glucose agar, malt extract agar and sheep blood agar. Using 
these media Candida grows as smooth to wrinkled textured colonies of white or beige color. 
Identification of Candida species should be conducted to species level for all organisms 
isolated from normally sterile body fluids and from most cultures of mucosal surfaces. The 
identification of different Candida species cames both prognostic and therapeutic significance. 
Although the germ tube test permits the distinction between C. albicans (germ tube-positive) 
and non-albicans Candida species (germ tube-negative), the detection of multiple yeast 
species in culture may be difficult and often time consuming. Differential and selective media 
have been developed by incorporating chromogenic or fluorogenic substrates directly into the 
growth medium (e.g. CHROMagar '3I, Sabouraud TTC ?26). The formation of colored colonies in 
which the coloration is species specific allows the direct (presumptive) identification of different 
Candida species on primary isolation. 
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ad с) The demonstration of organisms morphologically consistent with Candida in tissue 
sections is the gold standard of demonstrating deep tissue Candida infection With appropriate 
special stains such as periodic acid-Schiff (PAS) and Gomom methenamme silver (GMS) yeast-
like bodies with pseudohyphae can be seen Histopathology allows at best a generic 
identification and culture of the same material may provide an identification to species level 
Furthermore the differentiation of Candida organisms from other opportunistic fungi such as 
Aspergillus Histoplasma or Tnchosporon cutaneum based on histologic examination alone may 
be difficult Since invasive procedures are required to obtain appropriate tissue specimens the 
use of histopathology is often precluded in patients with severe thrombocytopenia 
Detection of Candida species in the bloodstream is a key clinical laboratory strategy for 
18 establishing a diagnosis of invasive candidosis Single positive blood culture or blood cultures 
from a vascular catheter growing Candida species should be considered significant until 
m 
~à_ proved otherwise However the diagnostic yield of blood cultures for detection of fungemia is 
Φ 
3 only 15-50% 138 The recovery of Candida species from b l o o d cultures m a y b e i m p r o v e d by t h e 
о 
(В use of biphasic m e d i a by vent ing the b l o o d culture bott le or the increase of cul tured v o l u m e 
-< 
3, of blood A major advance was constituted by use of a lysis centrifugaron blood culture system 
• < 
j This system was superior to other systems with respect to both the overall rate of recovery and 
^ the time to recovery Although data to evaluate the recovery of Candida from blood 
о specimens with fully automated blood cultunng systems (e g BactAlert Bactec 9240) are 
â scarce there are data that support an increased recovery and earlier detection of yeast cells 
о 
5 by automated systems when compared to conventional cultunng methods 24° However 
Φ 2- invasive candidosis remains difficult to diagnose and the above mentioned diagnostic 
о 
methods often lack sensitivity in early recognition of this infection Investigational non-cultural 
diagnostic systems are being developed to facilitate diagnosis more rapidly and improve 
therapeutic monitoring Detection of antigens genomic fragments and metabolites are now 
under investigation although no single system will supplant the standard diagnostic tools 
Investigational strategies for detection of antigenic markers include the detection of cell wall 
mannan by radioimmunoassay or latex agglutination Candida enolase by immunoassay 227 d-
arabmitol by gas-liquid chromatography 57 or 1 3-B-D-glucan by amebocyte lysate assay '2 I 
Technical complexity poor reproducibility or positive results in patients only colonized with 
Candida species are problems which have to be overcome and are currently undergoing 
more extensive investigation At present no firm recommendation about any of the antigen 
tests can be given for the routine diagnostic laboratory Another approach involves the 
detection of Candida DNA fragments by polymerase chain reaction (PCR) Circulating 
Candida genome was detected by PCR in blood-specimens collected from mice with invasive 
candidosis while those from mice only colonized in the gastrointestinal tract with Candida 
remained negative 215 PCR promises to be more sensitive than blood cultures and may be an 
adequate technique in the early detection of invasive candidosis although the true relevance 
and utility of this test remains to be established. Improved assay's may be useful indicators of 
deep infections in neutropenic patients complementing the diagnostic utility of blood cultures. 
Susceptibility testing 
Until recently, "rolling dices" was probably equally accurate (but much cheaper) in order to 
determine clinically useful in vitro susceptibility data for tnazole antifungals. MIC results of 
different antifungal susceptibility testing methods were shown to vary as much as 50,000-fold 
53
. The major sources of variation in susceptibility testing have been attributed to the choice 
of medium and pH, inoculum preparation and size, incubation temperature and time, and 
end-point criteria. In 1992, after nearly 10 years of development, the National Committee for 19 
Clinical Laboratory Standards (NCCLS) published a tentative version of their reference
 m 
method for broth dilution susceptibility testing for yeasts 5 2 1 6 5. While not without flaws, and g-
being depending on individual host factors, this standardized, reproducible method allows 5 
о 
multiple investigators to generate data, based on correlation between antifungal MIC and < 
о 
clinical outcome. Detailed review of the NCCLS guideline and of the current status of the ζ 
correlation of in vitro data with clinical outcome is given in the above mentioned | 
publications, and a minireview by Ghannoum et al. 56. Despite the recent advances in <-> 
a 
antifungal susceptibility testing no definitive correlation between the results of in vitro a 
a 
susceptibility testing and in vivo response could be established. In the present situation routine 9 
antifungal susceptibility testing of yeasts should therefore be discouraged, with the exception о 
δ 
of isolates from blood cultures. 2 
Clinical manifestations 
In general Candida infections are classified as localized or deep-seeded (Table 6). The 
terminology applied to describe "hematogenous" Candida infections has been used with 
great inconsistency. Bodey et al . I B suggested a standard terminology dividing hemato­
genous infections into three groups: 
A Candidemia is the occurrence of any Candida species in one or more blood cultures. An 
association with clinical symptoms or intravascular catheters should be specified. 
B. Acute disseminated candidosis is defined as a proven infection of multiple non-contiguous 
organs due to hematogenous seeding, including candidemia with skin lesions or 
endophthalmitis 
С Chronic disseminated candidosis, formerly hepatosplenic candidosis, in patients during 
periods of prolonged neutropenia. 
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If not separately stated, the description of clinical manifestations are derived from different 
standard text books, including those of Odds'2 8, Dupont4 2, and Bodey'7. 
Table 6: Clinical manifestation of Candida infections 
Localized, muco-cutaneous infections 
• skin and nail infections 
• thrush/oropharyngeal infections 
• chronic mucocutaneous candidosis (CMC) 
• vulvovaginitis and balanitis 
• esophagitis 
• gastro-intestinal candidosis 
Deep-seated candidosis 
• peritonitis and intra-abdominal abscess 
• meningitis 
• endocarditis 
• urinary tract infection 
• osteoarticular candidosis 
• ocular candidosis 
• candidemia 
• chronic-disseminated candidosis 
(D 
О 
° Cutaneous candidosis 
Cutaneous candidosis includes intertrigo (Figure 3), diaper candidosis (Figure 4), paronychia 
and onychomycosis (Figure 5). Predisposing factors of this common candidal infection are 
occluded moisture (diaper, bandages, wet bathing suits), heat, disruption of the epidermal 
barrier (friction/maceration), hormonal changes, obesity, diabetes mellitus, antibiotic 
treatment and immunosuppression. Common location are the moist folds of skin such as 
axillae, groin, intergluteal, or sub-mammary folds, and the interdigital spaces of fingers and 
toes. The lesions consist of a moist, macular erythematous rash with typical "satellites" on the 
surrounding healthy skin. 
Paronychia of the finger nails may be seen as an occupational hazard in persons whose 
hands are subject to constant wetting or consistent occlusion (gloves), leading to maceration 
of the cuticle (nail fold). Lesions are characterized by mild to moderate erythema of the nail 
fold, associated with moderate discomfort. In chronic cases the infection may progress to 
cause onychomycosis, characterized by a complete destruction of the nail tissue. The last is 
more or less exclusively seen in patients with chronic muco-cutaneous candidosis. 
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Figure 4: Diaper candidosis 
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Figure 5: Onychomycosis 
Figure 6: Vulvovaginal candidosis 
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The treatment of cutaneous candidosis depends on the extent and location of disease and 
the host's defense Topical therapy such as clotrimazole miconazole or ketoconazole may 
be given to a d d systemic treatment or alone in less extended infections The selection of the 
form (powder or ointment) depends on the local skin condition Extensive infections 
especially in compromised hosts should be treated systemically Classically oral ketoconazole 
was used but newer oral or parenteral azoles (fluconazole itraconazole) are advantageous 
In general antifungal treatment should be accompanied by restoring the epidermal barrier 
by keeping the infected area dry and cool 
Chronic mucocutaneous candidosis 
23 
Chronic mucocutaneous candidosis is a form of persistent and recurrent Candida infection of 
the skin nails and mucous membranes practically exclusively caused by С albicans The g-
clinical features include oral esophageal and vaginal candidosis as well as infections of the 5 
о 
skin and nails Skin lesions are painless crusted with mild inflammation but the extent of ? 
о 
cutaneous involvement varies Candida granuloma is the most severe localized form with % 
hyperkeratotic granulomatous lesions (horn formation) Chronic mucocutaneous candidosis g 
is mainly seen in young children and AIDS patients with impaired Τ lymphocyte function
 n 
о 
The occurrence of this disorder should alert physicians to the possibility of a defect immune g 
а 
system ? 
Topical treatment may initially be used in patients with limited cutaneous infections but in η 
δ 
general systemic antifungal therapy with orally administered azoles is necessary Whereas 2 
cutaneous and mucous lesions improve already after 1-2 weeks of systemic antifungal 
therapy most nail infections need to be treated for several months Additionally attempts 
should be undertaken to correct the patient's immune deficiency 
Vulvovaginal candidosis and balanitis 
Candida infections of the genital tract are mainly seen in pregnant women (last trimester) 
during or after broad spectium antibiotic treatment and patients with diabetes mellitus 
Other predisposing factors may be low vaginal pH tight synthetic clothing sexual activity 
lUDs oral contraception with high estrogen-content dietary practices and specific 
immunologic defects l i 0 Clinical symptoms include vulval pruritus vaginal discharge and 
dyspareunia and may increase shortly before onset of menstruation Typically the 
discharge is creamy white and curd-like (Figure 6) The erythematous inflammation may be 
limited to the genital mucosa but may extend to include the perineum and the entire 
inguinal area In HIV /AIDS patients the infection may be chronic and refractory to 
treatment 
Inlroduclion 
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Figure 7: Trush 
Figure 8: Candida esophagitis 
Chapter 1 
α 
о 
Candida balanitis is characterized by pruritus, erythema, and gray-white pustules on the 
glans penis or preputium Despite the tact that it is still unknown to which extend sexual 
transmission occurs, the sexual partner should be investigated for vulvovaginitis. 
Candida vaginitis can be treated with topical polyene and azole compounds in a variety of 
formulations. The clinical efficacy is not influenced whether lotions, creams, vaginal tablets, 
or suppositories are used. Short or single-dose oral treatment is possible, due to the use of 
higher doses of mainly azole antifungals. In women with recurrent and chronic infections, 
initially predisposing factors should be investigated and if possible eradicated. After initial 
topical or oral therapy, maintenance treatment with low dose oral azole compounds is 
recommended. 25 
m 
Oropharyngeal candidosis a. 
1 
о 
о 
The clinical features of oropharyngeal candidosis includes pseudomembranous candidosis (= S 
о 
thrush. Figure 7), glossitis, stomatitis, and perleche (angular cheilitis). The infection is associated ^ 
with different endogenous and exogenous predisposing factors, such as immunologic | 
impairment due to age (neonates), diabetes mellitus, leukemia, malignancy, neutropenia, η 
о 
HIV infection, and the use of histamine antagonists. The combined use of broad-spectrum g 
antibiotics and steroids was demonstrated to cause Candida laryngotracheitis in otherwise 
healthy patients 2e. In patients with thrush the oral mucosal surface is covered with whitish, 
creamy pseudomembranes, consisting of hyphae, yeast cells, bacteria, and cell debris. 
Removal of plaques will expose a erythematous, bleeding, and possible painful mucosa 
Spreading of the infection may cause glossitis. Stridor or hoarseness of unknown cause in an 
immunocompromised patient may be caused by Candida epiglottitis7. 
Stomatitis occurs in patients with dentures and may lead to generalized hyperemia and 
granular inflammation of the predominately maxillary prosthesis. The infection may involve the 
angles of the mouth, causing localized fissures (perleche). 
Despite the fact, that fluconazole (p.o. 100 mg/d ) can be easily administered and is highly 
effective its use should primarily be avoided to reduce the chance of resistance 
development Instead, non-absorbable, topical antifungals such as nystatin suspension or 
clotrimazole troches should be initially used. 
Esophaqitis 
Esophagitis often develops in AIDS patients or patients treated for leukemia and solid tumors. 
Patients suffer from painful dysphagia with retrosternal chest pain and burning sensation. 
Vomiting and nausea may occur. Although 30% of the patients have oral candidosis, the 
presence or absence if either one of the infections (thrush and esophagitis) is independent 
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from each other. To diagnose the infection, endoscopy (including brush specimen or biopsy) 
seems superior to (barium contrast) radiographs. It is still discussed whether primarily the 
response to empiric antifungal treatment should be assessed in order to differentiate 
between candidal and non-candidal esophagitis, before other diagnostic measurements are 
taken. Endoscopic findings show creamy whitish pseudomembranes, intense inflammation, 
and superficial ulcers (Figure 8). In general, clinical, radiographic, and endoscopic findings 
must be differentiated from other causes of esophagitis, especially viral infections (Herpes 
simplex - and cytomegalovirus), and non-infectious conditions such as esophageal Kaposi's 
sarcoma, stenosis, idiopathic ulcers, and peritracheal non-Hodgkin lymphoma іэз.134 
Despite isolated reports of successful topical treatment, systemic therapy (eg. 100-200 mg p.o. 
26 or i.v. fluconazole) is recommended. Commonly the intravenous formulation is advantageous 
since patients cannot tolerate oral treatment. The exact duration of treatment is unknown, 
m 
but should be continued for at least 10 days after resolution of symptoms 20°. Especially in 
a 
3. AIDS patients with recurrent esophagitis, maintenance treatment is suggested. 
Table 7: Endogenous and exogenous factors predisposing to gastrointestinal 
candidosis 
old and young age 
diabetes mellitus and other endocrinopathies 
mucocutaneous candidosis 
AIDS 
defect phagocytic function 
chemotherapy (via disruption of mucosal barier) 
Broad-spectrum antibiotics 
Corticosteroids and other immunosupressive agents 
Antacids 
Duration of hospitalization 
Drains 
Gastrointestinal candidosis, peritonitis and intra-abdominal abscess 
Superficial candidosis of gastrointestinal mucosal surfaces is commonly seen in patients with 
malignancies or surgical intensive care patients. Other predisposing factors are listed in table 
7. The infection usually is asymptomatic during life, only diagnosed at autopsy. Lesions can be 
found at any site in the gastrointestinal tract. Progression and perforation may lead to 
hematogenous spread into organs, or cause peritonitis. 
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Exogenous 
Candida peritonitis can furthermore result from other perforations due to ulcers, colitis, 
neoplasma, or surgery, and may also originate from colonized CAPD catheters Unless 
patients are severely immunocompromised, the infection remains localized to the abdominal 
cavity Occasionally, Candida may cause, pancreatic abscess, cholangitis, and biliary tract 
infection 
One of the most controversial aspects in the diagnosis of Candida infections is probably the 
clinical significance of Candida isolation from intra-abdominal sources In general, patients 
undergoing surgical treatment have a low risk of disseminated infection, even if Candida is 
isolated from their peritoneal fluid or an intra-abdominal abscess1 7 3 Candida should only be 
considered as clinically important, when isolated from intra-abdominal foci of "high-risk" 
patients, who received immuno-supressive therapy or had prior episodes of sepsis 3 5 8 In 27 
addition to antimicrobial treatment of bacterial co-pathogens, and adequate drainage, 
m 
these patients should receive 400 mg once daily fluconazole o. 
3 
о 
о 
Ocular candidosis (§ 
o 
• < 
Candida endophthalmitis implies hematogenous dissemination to multiple organs in patients | 
with candidemia or catheter-associated infection Rarely, exogenous infection may occur
 n Ü 
following ocular trauma or surgery The infection is commonly caused by С albicans In a g. 
review based on the English-literature between 1965 and 1989 only 6 well documented cases 
were found 7A The incidence of non-albicans endophthalmitis due to С parapsilosis and 
С tropica/« might be increasing 3 1 4 5 
Lesions are commonly located near the macula leading to impaired (cloudy) vision In 
general ophthalmologic consultation is recommended to establish the diagnosis, to assess 
the clinical response, or to detect complications of hematogenous Candida infections 
The standard treatment consists of iv amphotericin В in combination with flucytosine l 8 8 
Recently, systemic treatment with fluconazole (with or without intraviteal amphotericin B) was 
shown to be effective 4S l 8 2 2 " , but still, partial vitrectomy may be indicated to prevent loss of 
sight 
Osteoarticular candidosis 
Candida joint infections may occur after direct inoculation during implant surgery or intra­
articular corticosteroid injections or by hematogenous dissemination The last is mainly seen 
as late complication in low birth-weight neonates neutropenic patients or patients with pre-
d a m a g e d joints (prosthetic or rheumatoid) Osteoarticular infections of the vertebra and 
sternoclavicular joints are frequently seen in iv drug abusers 
The symptoms of Candida arthritis include fever indolent pain and effusion In infections due 
to hematogenous spread usually more than one joint is involved 
o. 
о 
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Pulmonary candidosis 
Pulmonary candidosis may follow aspiration from the colonized upper respiratory tract, 
resulting in a local or diffuse bronchopneumonia, or may result from seeding of the lung 
during hematogenous spread, resulting in nonspecific, patchy infiltrates affecting both longs. 
Contrary to previous studies in cancer patients with Candida pneumonia Haron et al. 6S 
found only a small proportion of cases with severe neutropenia and a surprising lack of other 
organ involvement or candidemia. Aspiration of oropharyngeal content was suspected as 
the main route of infection in these patients. The major clinical presentations were fever and 
28 tachypnoe. Since the isolation of yeasts from respiratory specimens (including BAL) and the 
radiologic and clinical presentation is nonspecific, most patients are diagnosed at autopsy. 
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Central nervous system (CUS) candidosis 
Among this very uncommon presentation of Candida infections, meningitis is the most 
ro frequent. The infection primarily occurs in low-birth-weight infants with hematogenous 
" candidosis and in patients with intracerebral devices, such as ventriculoperitoneal shunts. 
и Symptoms include hydrocephalus, fever, and meningeal irritation, but the course of disease 
о may be indolent with minimal fever 177. In shunt infections the recommended treatment is 
¡у replacement of the shunt and ¡v (and intrathecally) amphotericin B. 
о 
δ Other forms of CNS candidosis include brain abscess and metastatic encephalitis, all of which 
are mainly diagnosed at autopsy. 
Cardiac candidosis 
Particulary in patients with prosthetic or previously d a m a g e d heart valves hematogenous 
spread of Candida may lead to the establishment of endocarditis, the most common form of 
cardiac candidosis. Other predisposing factors are central venous catheters and iv drug 
abuse. Clinical symptoms are similar to those of bacterial endocarditis, but embolic 
phenomena may even be more frequent in fungal infections. 
The treatment consists of antifungal therapy and surgical repair/replacement of the valves. 
Regarding the antifungal treatment, amphotericin В in combination with flucytosine is 
recommended, followed by long-term fluconazole maintenance 219246 
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Urinary tract candidosis 
Due to the lack of well-established guidelines, fungal urinary tract infections (UTI) present a 
diagnostic and treatment dilemma 62. The recovery of Candida species from urine cultures 
may be consistent with asymptomatic colonization, local infection, or might be the first 
symptom of systemic fungal infection. The clinical significance largely depends on the 
patient's clinical condition. 
Despite apparent problems as to which candidal colony count to use as a threshold, 
accurate diagnostic is needed to ensure necessary treatment and prevent avoidable 
adverse events in patients without need of toxic antifungal treatment. 
Most lower UTIs result from a local spread of yeasts from the genital- and gastrointestinal tract. 29 
Candida cystitis or bladder colonization is usually seen in patients with prolonged
 m 
•g 
catheterization in combination with antibiotic treatment, diabetes mellitus, or by mechanical g-
obstructions that lead to incomplete bladder emptying (anatomical abnormalities, prostatic о 
о 
hypertrophy, cervical cancer). < 
о 
Candida pyelonephritis is usually a result of hematogenous dissemination, but may % 
furthermore occur due to ascending infection. Infection may be complicated by g 
development of "fungus balls" in the renal pelvis. η 
Q 
Amphotericin В bladder irrigation is a common mode of therapy for uncomplicated g 
a 
candiduria, although no specific guidelines exists as to the optimal dose and best manner of ° 
administration. Traditionally 50 mg/l amphotericin В was used, but recently doses as low as 5- о 
5 
10 mg/l were recommended ,θ0. According to a recent literature review the therapy of 3 
choice might be oral fluconazole (50-200 mg/d) which appears to be of clinical value in the 
treatment of both uncomplicated and complicated candiduria 224. 
Candidemia 
Candidemia used to be a rare disease limited to patients with burn wounds and other severe 
traumas. Candida spp. were therefore classified as harmless commensals. During the past 
decades, the enlarging proportion of patients in need of chemotherapy, transplant surgery 
and intensive care, was paralleled by a steady increase in the incidence of nosocomial 
Candida infections , 3 7 2 . In US hospitals, the incidence of candidemia increased by two- to 
fivefold and one- to fourfold in teaching and non-teaching hospitals, respectively 8 1 M , with 
Candida species being the fourth or even third most common pathogen isolated from blood 
cultures ш 'w. 
Despite antifungal treatment, the mortality of candidemia is still as high as 60%, with an 
attributable mortality of 38% (Cl?s: 26-49) 237. In those patients surviving candidemia the 
average hospital stay is prolonged by 30 days, compared to patients without Candida 
Introduction 
infections 237 Candidemia therefore is not only a life-threatening yeast-infection but 
furthermore significantly increases the costs of health care 
Candidemia remains a difficult entity to treat The need to adopt treatment to the individual 
patients complicates the development of uniform therapeutic recommendations Regarding 
the frequency of hematogenous dissemination its high mortality and the difficulties to 
establish accurate bedside diagnosis all patients with candidemia regardless of its source or 
duration should be treated 2250в7200237 Terms as ' b e n i g n ' candidemia should be 
abandoned The question remains which antifungal to use in which doses for how long and 
if it should be given alone or in combination In patients with catheter related candidemia 
the removal of the indwelling device seems essential to eradicate the yeasts 4 3 8 7 Failure to 
30 perform catheter exchange was strongly associated with the persistence of candidemia in a 
study by Rex et a l , 6 2 
m 
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i Chronic disseminated candidosis 
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2· Chronic disseminated candidosis formerly referred to as hepatosplenic candidosis is seen in 
• < 
J patients with severe neutropenia particularly due to acute leukemia Histology is 
3 
о characterized by diffuse necrotic lesions or abscesses in the spleen and/or liver Typically the 
η § infection begins during a period of prolonged neutropenia and presents as fever with liver 
g 
g- enzyme disturbance after hematologic remission and recovery of neutrophil count Clinically 
5, abdominal pain and enlargement of the liver and/or spleen may be detected Diagnosis 
g may be hindered by the inability to receive diagnostic material (biopsy) and the fact that 
blood and biopsy cultures remain negative despite visible (pseudo-)hyphae in the lesions 
Numerous small radiolucent lesions in the liver or spleen may be detected by CT scans or 
ultrasound 
Classically amphotericin В was used for the treatment of patients with chronic disseminated 
candidosis Recent studies suggest that fluconazole therapy may be at least equally 
effective and better tolerated 5 3 6 
Antifungals used in the treatment of candidemia and deep-seated infections 
Until recently there have been very few systemic antifungals and amphotericin В was 
considered as the golden standard However clinicians were reluctant to use the drug since 
they were appal led by its adverse effects Due to its ease of administration and safety 
fluconazole seemed promising but until confirmed by Rex et al '6 3 it was unknown that 
amphotericin В and fluconazole are similarly effective in the treatment of non neutropenic 
patients with primarily catheter-related candidemia Fluconazole was furthermore proven to 
be effective for various candidal infections including renal disease hepatosplenic 
candidosis and deep organ candidosis in organ transplant recipients and patients with 
Chapler 1 
hematological mal ignancies S 3 6 7 i " 8 1 3 5 . In surgical patients the combination of amphotericin 
В (0.5 mg/kg) and flucytosine (4 χ 25 m/kg) lead to an earlier microbiological response, but 
cure rates were identical to those of fluconazole monotherapy e3. With the probable 
exception of acute hematogenous candidosis in neutropenic patients all (tri)azoles can be 
effective alternatives to amphotericin В (± flucytosine) for selected systemic candidal 
infections. 
Amphotericin В 
The polyenes include three main compounds: natamycm, nystatin, and amphotericin B, of 
which only the last can be used parenterally in the treatment of systemic fungal infections. 
Amphotericin В is a naturally occurring compound produced by Streptomyces nodosus. It _31 
b e c a m e the treatment of choice in patients with candidemia and deep-seated infections,
 m 
aspergillosis, and zygomycosis right after its introduction in the late 1950. The clinical effect of §· 
amphotericin В is due to its irreversible binding to ergosterol of the fungal cell membrane. The 5 
о 
major disadvantage of the conventional formulation of amphotericin В is the high incidence -< 
of adverse reactions, often leading to early termination of treatment (Table 8). The total dose -s 
of conventional amphotericin В is limited to 4g since renal tubular d a m a g e is predictable in g 
Ö 
patients exceeding this cumulative dose. Meanwhile some of the early adverse reactions о 
о 
might be prevented by slow built up of dosage, or co-administration of antihistamines, the g 
a 
major problem of nephrotoxicity remains almost unchanged. Considerable effort has been ? 
expanded in the quest for less toxic drug analogues and different formulations. The various о 
5 
lipid formulations of amphotericin В were shown to significantly reduce the toxicity and be 2 
equally effective, using a dosage of up to five-times the one of the conventional 
amphotericin B. 
Flucytosine 
Flucytosine inhibits the protein synthesis of yeasts. The penetration of the drug into body 
cavities, including the cerebrospinal fluid is good, but it's clinical use is limited by the common 
occurrence of primary resistance and development of resistance during treatment. 
Furthermore, flucytosine can suppress the bone marrow, especially limiting its use in AIDS 
patients. Flucytosine in combination with (reduced dosages) amphotericin В was shown to 
be effective in patients with persistent candidemia and/or deep-seeded candidosis involving 
the liver, spleen, bones, CNS, or the heart4». 
Azoles 
The azoles are divided into the older imidazoles (miconazole and ketoconazole) introduced 
in the early 1980's, and the newer triazoles, fluconazole and itraconazole, introduced in 1990 
and 1992, respectively. The main antifungal effect of the azoles is through inhibition of the 
Inlroduclion 
ergosterol synthesis, thereby interacting with the main sterol in the fungal cell membrane, 
leading to an increased permeability and obstruction of cell growth. 
Table 8: Adverse effects of antifungal agents used in the treatment of systemic 
candidos« 
(Organ) 
system 
Gl tract nausea 
vomiting 
anorexia 
diarrhea 
abdominal pain 
Skin rash 
pruritus 
Stevens-
Johnson-
syndrom 
Liver elevation 
plasma 
aminotransferas 
e 
hepatitis 
Bone anemia 
marrow leukopenia 
thrombocytope 
nia 
Kidney azotemia 
tubular acidosis 
hypokalemia 
hypomagnese 
mia 
Endocrine adrenal insuf-
system ficiency 
decreased 
libido 
impotence 
gynecomastia 
Other (thrombo)phleb 
itis 
headache 
fever & chills 
confusion 
hypertension 
edema 
photophobia 
seizure 
dizziness 
Amphotericin В 
+ 
+ 
+ 
+ 
+ 
80% 
+ 
+ 
+ 
+ 
+ 
+ 
Flucytosine 
5% 
5% 
+ 
+ 
+ 
+ 
7% 
rare 
less common 
+ 
+ 
+ 
+ 
Ketoconazole 
<10% 
<10% 
+ 
+ 
+ 
+ 
2-10% 
+ 
rare 
+ 
+ 
+ 
+ 
+ 
+ 
Fluconazole 
<5% 
<5% 
+ 
1-7% 
rare 
+ 
+ 
Itraconazole 
<10% 
<10% 
+ 
+ 
1-5% 
rare 
+ 
rare 
+ 
+ 
+ 
+ 
adapted from Como and Dismukes32 
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Table 9: Characteristics of antifungal agents used in the treatment of systemic candidosis 
Characteristics 
Trade n a m e 
Formulation 
Oral bio-availibility 
Protein binding 
U n c h a n g e d drug 
in urine 
CSF c o n c e n t r a t i o n 
Peok pldsma 
c o n c e n t r a t i o n 
(ng/mi) 
Terminal 
elimination half-life 
Dialysable 
Renal insufficiency 
Supplemental 
dose after HD 
Contra indicdt ion 
Increases plasma 
c o n c e n t r a t i o n of: 
Decreasing azole 
plasma c o n c e n ­
tration 
Resistance 
Dosage 
Adults 
Dosage 
Children 
Comments 
Amphoter ic in В 
Fungizone® 
p o or iv 
-
++ 
-
-
1.2-2.0 
20-24 h 
(end-phase 15 d) 
H D -
PD-
no adjustment 
necessary 
not required 
potent ia l rendi 
failure 
severe hepat ic 
failure 
С lusitaniae 
0.6-1 m g / k g / d 
q24h 
(daily increase of 
0.1-0.25 m g / k g , 
maximum total 
dose: 5q) 
0.6-1 m g / k g / d 
b l o d d e r irrigdtion 
10-50 mg/l 
intrathecal: 0.2-
0.5 m g q48-72h 
(di luted with CSF 
or qlucose) 
a d d heparin to 
r e d u c e 
thrombophlebit is 
Flucytosine 
Ancotil® 
p o o r i v 
++ 
--
++ 
++ 
30-45 
3-6 hr 
HD + 
PD + 
extend ¡ntervdl 
37.5 mg/kg q6h 
pregnancy, 
neonates 
up to 50% prim-
arily resistant 
37.5 mg/kg q6h 
37.5 mg /kg q6h 
use in comb ina-
tion with other 
antifungals 
Ketoconazole 
Nizoral® 
p o 
+ 
pH dependen t 
++ 
-
-
1.5-3.1 
7-10 hr 
HD-
PD-
no adjustment 
necessary 
not required 
pregnancy, 
lactat ion 
cyclosporine 
cumarines 
Phenytoin 
antacids 
Pb-antagonist 
isoniazid 
Phenytoin 
rifampin 
C. »cruse/ 
C. qlabrata 
200-400 mg q24h 
3.3 - 6.6 mg /kg 
antagonism with 
AmB 
not 
r e c o m m e n d e d 
for systemic 
infection 
Fluconozole 
Diflucan® 
po* or ¡V 
++ 
-
++ 
++ 
10.2 
22-31 hr 
HD + 
PD? 
CrCI < 40 
ml / min 
200 mg , 
CrCI <20 
ml/min 
100mq/24h 
200 mg 
pregnancy, 
lactat ion 
cyclosporine 
cumarines 
Phenytoin 
rifampin 
С krusei 
C. qlabrata 
200-400 m g 
q24h, initially 
o n c e 400 m g 
6-12 m g / k g 
q24h 
penetrates 
well into CSF 
Itraconazole 
Trisporal® 
p o * (iv under 
investiqqtion) 
+ 
pH d e p e n d e n t 
++ 
-
-
0.2-0.4 
24-42 hr 
HD 
PD 
not required 
p r e g n a n c y , 
lactat ion 
cyclosporine 
cumarines 
(phenytoinj 
(diqoxin] 
antacids 
H2-dntdgonist 
Phenytoin 
r ifampin 
2 0 0 q l 2 h 
tablets and suspension 
- no/very low, - low, +/- middel. + = high, ++ very high, HD = hemodialysis PD = peritoneal dialysis 
Introduction 
Table 10: New and future antifungal agents 
Generic 
Liposomal amphotericin В 
Amphotericin В Lipid 
Complex 
Amphotericin В colloidal 
dispersion 
Long-circulating pegylated 
AmB liposomes 
Liposomal nystatin i.v. 
Terbinafine 
Itraconazole i.v. 
Fluconazole - high dose 
ER-30346 
Sch 510448 
D807 
D8581 
UK-109.496 (voriconazole) 
UR-9746 and UR-9751 
LY 121.019 (cilofungin) 
LY 303366 
L-733560 
BMS-18118 
Syringomycin E 
Trade name 
AmBisome 
Abelcet 
Amphocll 
Nyotran 
Lamisil 
Trisporal 
Diflucan 
Comment 
licensed , unilamellar liposomal vesicle 
licensed in USA sheets 
micelle, licensed 
tested in vitro 
clinical phase Ila studies, III unaerway 
old po drug new indications ? 
triazole, under clinical investigation 
under clinical investigation 800-1600 mg/d 
triazole, tested in vitro 
azole, tested in vitro 
triazole, tested in vitro (?) 
triazole, tested in vitro 
triazole, under clinical investigation 
triazole, tested in-vitro 
echinocandin В antifungal, tested in-vitro 
pneumocandin antifungal, tested in-vitro 
pradimicin, tested in-vitro 
lipodepsipeptide, tested in vitro 
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Azoles fcont.ì 
In contrast to fluconazole, the bioavailability and absorption of oral ketoconazole and 
itraconazole is influenced by the stomach pH, thereby altered by the presence of food or 
gastric acid 175 Ketoconazole and itraconazole are almost exclusively excreted in feces and 
urine, after metabolisation in the liver The proportion of the drugs excreted unchanged via 
urine is so little that doses need not to be adjusted in patients with renal impairment In 
contrast, fluconazole doses must be reduced in patients with a glomerular filtration rate of < 
50 ml/minute, since 80% of the administered dose is excreted unchanged in the urine The 
most important drug interactions are listed in table 9 Since ketoconazole, and rarely the 
tnazoles, may cause clinically important, even fatal hepatitis, azole therapy always should be 
discontinued in patients with symptoms of laboratory evidence of hepatic dysfunction 102 ni 35 
2,3
 In general, the azoles, especially the tnazoles, are a safe and effective alternative to
 m 
amphotericin В for the treatment of systemic Candida infections In patients with g· 
ketoconazole refractory candidosis, in vitro cross resistance to tnazole antifungal's and in one §. 
о 
case clinical treatment failures were demonstrated m Potential problematic, might be the < 
о 
development of resistance and/or selection of primary resistant Candida species during % 
treatment with azole antifungals | 
ñ 
η 
о 
In case of the newest treatment options (Table 10) such as the lipid or liposomal preparations g 
a 
of amphotericin В not only the clinical effect must be determined, but furthermore the ? 
economic implications since these preparations are extremely expensive Next to liposomal о 
δ 
amphotericin В a huge variety of new azole and tnazole compounds, liposomal formulation 2 
of other antifungals, and new dosages of clinically used antifungals (1600 mg fluconazole) 
are in development or are clinically evaluated 
Emergence of non-Candida albicans species and antifungal resistance 
As mentioned above С albicans used to be - and to a lesser degree still is - the Candida 
species predominantly isolated from clinically important sites Recently, infections are 
increasingly caused by other Candida species, such as С tropicalis С parapsilosis, С krusei 
and С glabrata β 4 2 4 2 In some institutions the proportion of non-albicans Candida isolates 
actually exceeded that of С albicans236 At the University Hospital Nijmegen the proportion 
of non-albicans Candida species increased from 12% in 1990 to 23% in 1995 (Table 11 ) 
With the exception of С tropicalis the virulence of non-albicans species seems to be 
comparable to that of С albicans 8 I The increase of С tropicalis infection in patients with 
leukemia is probably due to a higher virulence of this species in this patient group in whom 
the gastrointestinal mucosal "barrier" is d a m a g e d through the use of cytarabme 2 4 3 Despite 
its high virulence (colonization with С tropicalis frequently leads to invasive infections) the 
introduction 
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mortality of С. tropicalis candidemia was shown to be lower than that of C. albicans " 6 . 
Certainly, more studies are needed to further evaluate the pathogenicity of С tropicalis and 
the other non-albicans species. Presently, all Candida species isolated from clinical relevant 
material should be classified as possible pathogen. 
Table 11: Frequency of Candida species isolated from clinical material at the University 
Hospital Nijmegen, 1990 to 1995 
Candida spp. 
total 
albicans 
glabrata 
krusei 
tropicalis 
parapsilosis 
lusitaniae 
others 
not-speciated 
non-albicans 
non-albicans 
1990 
1604 
1406 
87.7% 
2 
0.1% 
2 
0.1% 
1 
0.05% 
23 
1.5% 
0 
0.0% 
49 
3.1% 
121 
7.5% 
198 
12.3% 
1991 
2258 
1867 
85.3% 
56 
24 
55 
53 
4 
44 
155 
391 
14.7% 
1992 
2659 
2190 
82.2% 
146 
20 
37 
39 
7 
35 
185 
469 
1 7.8% 
1993 
2456 
1966 
80.0% 
180 
39 
68 
45 
8 
62 
88 
490 
20.0% 
1994 
2393 
1895 
79.2% 
228 
42 
72 
61 
6 
47 
42 
498 
20 8% 
1995 
2579 
1979 
76.7% 
263 
10.2% 
119 
4.6% 
92 
3.7% 
54 
2.1% 
20 
0.7% 
48 
1.9% 
4 
0.1% 
600 
23.3% 
With the recent clinical use of new azole compounds not only a shift among the Candida 
species involved in nosocomial infections is discussed, but furthermore the development of 
resistance 2U. Next to the extensive use of new antifungals, and the changing patient 
population, the application of standardized antifungal susceptibility tests and the use of 
molecular typing methods may be other reasons to explain the current epidemiological 
trend. Not only, that the use of this method allow us to better understand the epidemiology of 
candidosis, but we are furthermore able to prove the development of resistance in sequential 
isolates of individual patients receiving antifungal treatment. 
Resistance of Candida spp. to amphotericin В appears to be extremely uncommon. 
Immunocompromised patients with candidemia due to isolates with amphotericin В MIC of > 
0.8 mg/l, were shown to have a significant higher mortality, compared to those whose 
Candida blood-culture isolates had an MIC of less than 0.8 mg/l (154). Aside from these 
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reports, primarily resistance and development of resistance to amphotericin В is well 
documented in C. lusitaniae 6i 132. Amphotericin B-resistant C. lusitaniae are increasingly 
isolated from hematology patients in the US, where amphotericin В is heavily used in the 
prophylaxis of this patient group 242 Recently, the development and spread of amphotericin 
В (and 5-fluorocytosine-resistant) C. lusitaniae strains within the hospital environment were 
reported ι«7Ί«ΐ7β. 
Meanwhile amphotericin B, due to its toxicity and cumbersome administration was restricted 
to patients with severe fungal infections, fluconazole is widely used for the (early) treatment of 
candidosis, possibly leading to resistance development or a shift towards non-albicans 
species. Furthermore, it is applied over long periods or even continuously in AIDS patients with 37 
remittent oropharyngeal candidosis. Subsequently, fluconazole resistance was not only first 
m 
reported in this setting »<« n» 125 '2' w , but is still hardly ever seen outside this group l 6 6. Most of Q. 
Φ 
these cases were advanced AIDS patients who had notable prior exposure to fluconazole. § 
0 
Resistant isolates g e n e r a l l y h a d a n e l e v a t e d MIC for f l u c o n a z o l e a n d w e r e g e n o t y p i c a l l y <Q 
о 
identical with the initial isolate, although reinfection during treatment with a genotypically CT 
different isolate may occur ' ". In those cases where development of fluconazole resistance j? 
occurred patients suffered from long lasting neutropenia, infections with intrinsically resistant " 
Û 
strains, such as C. kwsei, failure to remove a potentially infected device, or received low dose ^ ä (100-200 mg per day) treatment 1 2 m i " , in a randomized multicenter trail of fluconazole о 
versus amphotericin В as treatment of non-neutropenic patients no significant increase in MIC j» 
among serial isolates from individuals with persistent Candida infections could be § 
demonstrated l 6 4. Therefore, in patients, others than those (AIDS patients) with recurrent 
oropharyngeal candidosis, who receive shorter courses of therapy the chances of resistance 
development are very low 144. A good clinical response to fluconazole treatment c a n still be 
expected, especially if an appropriate dose (>400 mg per day) is given, and intrinsically 
resistant species, such as C. krusei. are ruled out. 
In general, available data illustrate the possibility of resistance development during 
fluconazole treatment and selection of inherently resistant strains ,6i. It seems that the shift 
from albicans to non-albicans species respectively from susceptible to less susceptible or 
resistant Candida strains is limited to a small group of severely immunocompromised patients, 
and patients treated for extended periods, or receiving long term prophylaxis with less than 
200 mg/d. Furthermore, other factors influence this shift, since some investigators could not 
demonstrate any association between the use of azole antifungals and the emergence of 
non-albicans species e i 8 6 . Despite the growing perception of azole-resistance and shifting 
proportions of Candida species as clinical relevant pathogens, the true incidence of the 
problem and strategies to prevent it are still unclear. 
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reports, primarily resistance and development of resistance to amphotericin В is well 
documented in С lusitaniae M l 3 2. Amphotericin B-resistant С lusitaniae are increasingly 
isolated from hematology patients in the US, where amphotericin В is heavily used in the 
prophylaxis of this patient group 242. Recently, the development and spread of amphotericin 
В (and 5-fluorocytosine-resistant) С lusitaniae strains within the hospital environment were 
reported ^пшил 
Meanwhile amphotericin B, due to its toxicity and cumbersome administration was restricted 
to patients with severe fungal infections, fluconazole is widely used for the (early) treatment of 
candidosis, possibly leading to resistance development or a shift towards non-albicans 
38 species. Furthermore, it is applied over long periods or even continuously in AIDS patients with 
remittent oropharyngeal candidosis. Subsequently, fluconazole resistance was not only first 
m 
5^  reported in this setting ' 4 4 ' " l 2 5 '2 ' '5', but is still hardly ever seen outside this group ' " Most of 
CD 
3 these cases were advanced AIDS patients who had notable prior exposure to fluconazole, 
о 
со Resistant isolates generally had an elevated MIC for fluconazole and were genotypically 
£, identical with the initial isolate, although reinfection during treatment with a genotypically 
~ different isolate may occur ' " . In those cases where development of fluconazole resistance 
¡=¡ occurred patients suffered from long lasting neutropenia, infections with intrinsically resistant 
о strains, such as C. krusei, failure to remove a potentially infected device, or received low dose 
о. (100-200 mg per day) treatment ігіб<і«. in a randomized multicenter trail of fluconazole 
о 
5 versus amphotericin В as treatment of non-neutropenic patients no significant increase in MIC 
ω 2- among serial isolates from individuals with persistent Candida infections could be 
о 
demonstrated l 6 4. Therefore, in patients, others than those (AIDS patients) with recurrent 
oropharyngeal candidosis, who receive shorter courses of therapy the chances of resistance 
development are very low l 6 i . A good clinical response to fluconazole treatment c a n still be 
expected, especially if an appropriate dose (>400 mg per day) is given, and intrinsically 
resistant species, such as С krusei, are ruled out. 
In general, available data illustrate the possibility of resistance development during 
fluconazole treatment and selection of inherently resistant strains 166. It seems that the shift 
from albicans to non-albicans species respectively from susceptible to less susceptible or 
resistant Candida strains is limited to a small group of severely immunocompromised patients, 
and patients treated for extended periods, or receiving long term prophylaxis with less than 
200 mg/d Furthermore, other factors influence this shift, since some investigators could not 
demonstrate any association between the use of azole antifungals and the emergence of 
non-albicans species в 5 6. Despite the growing perception of azole-resistance and shifting 
proportions of Candida species as clinical relevant pathogens, the true incidence of the 
problem and strategies to prevent it are still unclear. 
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Antifungal prophylaxis in patients with neutropenia 
To prevent hematogenous fungal disease in patients with neutropenia, antifungal agents are 
prophylactically used. Recently, antifungal prophylaxis has focused on the azoles, especially 
fluconazole, which was shown to reduce the frequency of hematogenous candidosis, and 
fungal-related death 58.170,245 η-,
θ u s e 0 f fluconazole as prophylactic anti-fungal increases the 
selection of resistant or less susceptible Candida species (C. krusei, C. glabrata) and other 
primarily resistant fungi, such as Aspergillus species, Zygomycetes, and Fusarium species. 
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Chapter 2.1 
Comparison of pulsed-field gel electrophoresis with isoenzyme 
profiles as a typing system for Candida tropicalis 
Bradley N Doebbeling, Paul F Lehmann, Richard J Hollis, Lung-Chi Wu, Andreas Widmer, 
Andreas Voss, and Michael A Pfaller 
Clinical Infectious Diseases 1993 16 377-383 
Abstract 43 
Candida species are important nosocomial pathogens, particularly in immunocompromised 
and critically ill patients. A variety of methods have been used to differentiate strains, but an 
optimal system has not been established. We compared methods for typing a panel of nine 
related isolates of Candida tropicalis from an outbreak of sternal wound Infections as well as 
four unrelated control isolates of this species. (The genetic relationships of the nine isolates in 
the panel had been confirmed previously by restriction fragment analysis). Typing was 
undertaken without knowledge of an isolate's origin. Karyotyping by contour-clamped 
homogenous electric field (CHEF) gel electrophoresis failed to distinguish between outbreak 
and control isolates. However, when chromosome-sized DNA was digested with SfTI, Eagl, 
Sacll, or Nael and the fragments were separated by CHEF electrophoresis, the outbreak 
isolates were readily identified. The isoenzyme profiles of the outbreak isolates were identical 
and were distinctly different from those of the control isolates. While both isoenzyme profiles 
and the modified CHEF procedure were discriminatory, the latter is recommended as a 
relatively convenient and reproducible technique for comparison of types of C. tropicalis. 
Introduction 
The Candida species have emerged as common pathogens in a variety of infections, 
including arthritis, osteomyelitis, endophthalmitis, myocarditis, meningitis, peritonitis, and 
vaginitis '2Θ '6 0 Recent data from the National Nosocomial Infections Surveillance System 
demonstrate that the overall frequency of nosocomial candidemia has increased by 219%-
487% m teaching hospitals and by 75%-370% in non-teaching hospitals over the past d e c a d e 
8 , 8 3
 Currently the Candida species are responsible for 8% of nosocomial bloodstream 
infections in the United States These species are etiologic agents of primary bloodstream 
infections which occur at a rate of 0 28-0 61/1 000 patients discharged from small and large 
hospitalsа 1 З 
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A number of nosocomial outbreaks of candidiasis have been reported, yet the significance of 
person-to-person transmission of Candida species has not been well documented in most 
situations. Outbreaks of infection due to Candida albicans have been reported in association 
with parenteral nutrition 123 and in both adult and neonatal intensive care units 2714S 206 216 
Candida parapsilosis has been reported as the etiologic agent in outbreaks of fungal 
endophthalmitis ,w and systemic infection related to parenteral nutrition 202233
 a n c | a n out­
break of Candida glabrata in a unit treating adult leukemic patients has been described 89. 
Recently, Isenberg and colleagues reported the first nosocomial outbreak of infection with 
Candida tropicalis; the fungus caused sternal wound infections in eight patients who had 
44 undergone coronary artery bypass surgery 7 I. An epidemiological investigation implicated a 
single scrub nurse, cultures of whose nasopharynx and fingertips yielded С tropicalis, as the 
m 
^ probable source of the fungus. When we typed the outbreak isolates by restriction fragment 
Φ 
3 analysis (RFA), using conventional electrophoresis in association with a computerized ¡mage 
о 
a analysis system, we were able to discriminate between outbreak and control strains 3 '. 
-< 
2. However, RFA may not be performed easily in all laboratories, and other procedures for 
• < 
¿3. typing yeasts may be more appropriate in different settings. In particular, typing procedures 
ñ involving isoenzymes "«20» and electrophoretic karyotypes " и и м з і и н е г і в have been used 
о extensively. Although distinct types of C. tropicalis can be detected by isoenzyme analysis209, 
5; the value of isoenzymes in discriminating between epidemiologically related and unrelated 
о 
5 isolates has not been assessed. Previous studies of this species with the use of contour­
en 
3- c lamped homogenous electric field (CHEF) gel electrophoresis have been limited, and simple 
karyotypes may not be useful in epidemiological investigations of С tropicalis outbreaks. 
Indeed, in one study, the electrophoretic karyotype of two different strains appeared 
identical u e . 
The outbreak described by Isenberg et al. 7' provides an excellent opportunity to evaluate 
the epidemiological utility of various typing methods when applied to a well-defined 
collection of C. tropicalis isolates from a point-source outbreak. Here we report on these 
isolates in terms of their isoenzyme profiles, their electrophoretic karyotypes, and their CHEF-
RFA types - i с , the pattern of DNA fragments produced when CHEF gel electrophoresis is 
applied to the resolution of pieces of nucleic acid cleaved from chromosome-sized DNA by 
"rare-cutting" restriction endonucleases. We contrast our findings with those obtained for the 
same isolates by RFA a lone 3 ' . 
Materials and Methods 
Candida isolates. Outbreak isolates included strains of С tropicalis from the sternal wounds of 
seven patients (isolates E3-E9) and from the nasopharynx and fingertips of the 
Chapter 2 
epidemiologically linked scrub nurse (isolates El and E2) from the cluster described by 
Isenberg et al. л . Isolates trom the remaining patient in the epidemic were not available for 
further study. Control isolates included four strains of C. tropicalis from epidemiologically 
unrelated, hospitalized patients. All yeasts were stored as suspensions in sterile water at 
ambient temperature until typed. The isolates were identified as C. tropicalis from their 
morphology on cornmeal agar and from their carbohydrate assimilation profile, which was 
determined with the API 20C system (Analytab Products, Plainview, NY). Each isolate was 
assigned a c o d e to allow typing without knowledge of its origin. 
CHEF electrophoresis. Two colonies (> 1 mm) of each yeast isolate were incubated overnight 
in 10 mL of YEPD broth (yeast extract, 10 g/L; peptone, 10 g/L; and D-glucose, 20 g/L). The 
cells were packed by centrifugation ( 1,000g, 5 min) and washed twice with 50 mM sodium 45 
EDTA (pH 8.0); a 130-pL aliquot of packed cells was then suspended in 580 pl_ of 50 mM 
m 
sodium EDTA (pH 8.0). The suspension of cells was evenly mixed with 100 pL of yeast cell wall- 3. 
degrading enzymes (Lyticase, L5263, partially purified grade; 1,250 U/mL in 50% glycerol 5 
о 
[vol/vol.], 0.01 Μ ΝαΡθ4, pH 7.5; Sigma Chemical, St. Louis) and 0.9 mL of 1% low-melting-point ί§ 
о 
agarose (SeaPlaque GTG, FMC BioProducts, Rockland, ME) at 58°C. Aliquots of 400 pL of the ~ 
yeast-agarose suspension were placed in individual molds (Bio-Rad, Richmond, CA) to form ? 
agarose plugs and were incubated for 2 hours at 37°C. Individual agarose inserts were
 0 
Q 
removed from the molds and incubated at 50°C for 15 hours in 2 ml of buffer (10 mM Tns-HCI, g 
a 
pH 7.5; 400 mM EDTA; 1% Sarkosyl) containing proteinase К (1 mg/mL; Protease type XXVIII, 20 В 
U/mg; Sigma). Agarose inserts were washed twice with 50 mM sodium EDTA (pH 8.0), η 
δ 
incubated overnight at 25°C, washed twice more, and then stored at 5°C 2 
• The chromosome-sized pieces of DNA were resolved on 0.7% agarose gels (SeaKem GTG, 
FMC BioProducts) by pulsed-field electrophoresis under conditions similar to those 
described by Monod et al.1 2 2 Saccharomyces cerevisae chromosome/DNA size standards 
(Bio-Rad) and DNA prepared from C. albicans were included in each gel as standards. In 
all instances electrophoresis was performed with a CHEF-DRII pulsed-field electrophoretic 
system (Bio-Rad). The conditions used for CHEF electrophoresis were modified in an . 
attempt to better resolve the chromosome-sized DNA. Agarose gel concentrations ranged 
from 0.6% to 1.0% (wt/vol.;, and voltages varied from 50 V to 150 V, with switch times 
ramped from 10 seconds to 360 seconds. The duration of electrophoresis varied from 3 
days to 6 6 days. The electrophoretic conditions that gave the best separation of the 
chromosomes were a 0.7% agarose gel (SeaKem GTG) at 150 V and 13°C. The pulse 
interval was 120 seconds for 24 hours followed by 240 seconds for 36 hours. The use of 
additional electrophoretic conditions to further differentiate among large chromosomes 
was unsuccessful. After electrophoresis, gels were stained with ethidium bromide, 
illuminated under ultraviolet light, and photographed with Polaroid 107C film (Polaroid, 
Cambridge, MA). 
CHEF-RFA For restriction endonuclease digestion, agarose plugs containing chromosome-
sized DNA were prepared as described above and placed into 100 mM Tns-HCI (pH 8 0) 
containing 5 mM magnesium chloride After two washes, the agarose inserts were p laced in 
100 μΐ of buffer containing 20 U of a "low frequency-cutting" restriction endonuclease 
Restriction endonucleases Sfil, Eag!, Sacll, and Nael were obtained from New England Biolabs 
(Beverly, MA) Overnight digestion was performed as directed by the endonuclease 
manufacturer CHEF pulsed-field electrophoresis was performed at 13°C for 24 hours at 200 V 
in a 1% agarose gel (SeaPlaque GTG) Pulse times were ramped from 10 seconds to 90 
seconds throughout the 24-hour period Photographs of ethidium bromide-stained agarose 
gels were inspected visually Each major and minor band was identified, and the distance 
46 from the origin of the gel relative to the lambda molecular weight standard was measured 
Isolates were considered different if any readily detectable band did not match In addition 
m 
о. the coefficient of similarity 3 ' was calculated for each isolate relative to an outbreak isolate 
i obtained from the index nurse A coefficient of similarity of >0 95 was considered to represent 
ю a match in banding patterns 
° Isoenzyme typing Crude extracts of С tropicalis yeasts were obtained by methods similar to 
Ij- those used previously ' 2 In brief, isolates were grown with shaking (150 rpm 72 hours, 28°C) in 
ñ 250 mL Erlenmeyer flasks containing 100 mL of broth (yeast nitrogen base without ammo 
о acids, 100 mM sucrose, 30 mM mannitol) The yeasts were harvested by centrifugaron and 
a 
a washed, they were then broken by beating with glass beads in the presence of 2 0 mM 
5, phenylmethylsulfonyl fluoride (Sigma) an inhibitor of proteinases 154 Isoenzyme profiles were 
Φ 
g- determined after native PAGE of the crude extracts in a Tns-HCI-glycine discontinuous buffer 
system where protein separation took place at pH 9 5 ' 2 After overnight electrophoresis, e a c h 
gel was washed twice with the buffer used for detection of enzyme activity and was then 
stained for the appropriate activity with the chromogenic reagents described previously 
(unless stated otherwise) 7 1 И Staining patterns for each enzyme activity were read, and the 
different patterns were assigned a code (a, b, etc ) The enzyme activities, together with the 
Enzyme Commission identifier, the amount of protein loaded per well, and the precentage 
(wt/vol) of Polyacrylamide used in the resolving gel, were esterase (EC 3 1 1 1 350 μд, 7 5% 
[chromogenic substrate, 4-methylumbelliferyl acetate]), a-glucosidase (EC 3 2 1 20, 350 μg 
7 5%) 0-glucosidase (EC 3 2 1 21, 350 mg, 5 0%) 5 0%) a -mannosidase (EC 3 2 1 24 350 μg, 
5 0% [chromogenic reagent, 4-methylumbelhferyl-a-D-mannopyranoside (Sigma, 67 mg/mL) in 
100 mM sodium acetate buffer, pH 5 5]) alkaline phosphatase (EC 3 1 3 1, 350 μg 5 0%) acid 
phosphatase (EC 3 1 3 2, 350 μg, 7 5%), glucose-6-phosphate dehydrogenase (EC 1 1 1 49, 
350цд 5 0%), malate dehydrogenase (EC 1 1 1 37, 350 цд, 7 5%) mannitol dehydrogenase (EC 
1 1 1 67, 350 μg. 7 5%) super-oxide dismutase (EC 1 15 1 1, 100 цд, 7 5%) and catalase (EC 
1 1 1 1 6 , 100 цд, 5 0%) 
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Results 
Typically, the CHEF-defined karyotype of the outbreak and control isolates of C. tropicalis was 
composed of three chromosome bands (figure 1, table 1). There were two exceptions in 
which four bands were seen; isolate E2, an outbreak isolate, had a faint large-sized extra 
band; and isolate U4, an epidemiological^ unrelated isolate, showed two small-sized bands 
(figure 1 ). Regardless of the different conditions used for electrophoresis, the basic three-band 
pattern remained for the majority of C. tropicalis isolates. The largest band of all of the isolates 
was not well resolved and may have contained a variety of pieces of DNA; indeed, there is 
the suggestion of an extra high-molecular-weight molecule in isolate E6, another isolate from 
the outbreak (figure 1). The karyotype of the C. albicans control, with eight bands resolved, 
differed greatly from that of C. tropicalis. 
Figure 2. CHEF-RFA electrophoresis of С tropicalis isolates 
after digestion with Sßl Outbreak isolates are shown in lanes 1-9 
Figure 1. CHEFelectrophoresisofC. tropicalis. Lanes 1-9 show
 J n d u n r e | a l e d c o n t ro l isolates in lanes 10 and 12-14. Lane 11 
outbreak isolates: lanes 10-13. epidemiological!)' unrelated iso-
 s | ) o w s t n e ( aii,,cans c o n t ro l . and lane 15 shows a С tropicalis 
lates; lane 14. С albicans, and lane Sc, S cerevisiae chromosome/ control (ATCC 13803) λ = lambda-phage DNA ladders (interval 
DNA size standards. Note the similari!) of the control and out- . 4g 5 motase pairs) as controls. Note the different banding pat-
break isolates. terns of the control isolates and the similarity of the outbreak iso-
LllL'S 
Far greater heterogeneity was found for the DNA fragment patterns obtained by the CHEF-
RFA technique when chromosome-sized DNA was digested with Sfil before CHEF gel 
electrophoresis. Each of the control isolates had a unique pattern that differed distinctly from 
the single pattern of fragments characterizing all of the outbreak isolates (figure 2, table I). 
Comparison of typing systems for Candida species 
Table 1. Comparison of RFA, CHEF gel electrophoresis, CHEF-RFA, a n d isoenzyme patterns 
in the molecular typing of C. tropicalis. 
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Note. Patterns observed on gels and isoenzymes types are shown, for example. In the form Al , a, A, a, and Aa, 
where these letters refer to the patterns associated with Isolates from the outbreak. Patterns distinctly different from 
that observed among outbreak isolates are referred to with consecutive letters, i.e., Bl, CI, Dl, El. or В, C, D, E. 
* Isolates E1-E9 were obtained from the outbreak; isolates U1-U4 were epidemiological^ unrelated 
¥ Data are from (39) 
a-GLU=a-glucosidase. ß-Glu= ß-glucosidase, EST=esterase, SOD=superoxlde dismutase, ACP=acld phosphatase, and 
GDH=glucose-6-phosphate dehydrogenase 
* d/a = either pattern a or pattern d 
When Eagl was used as the restriction endonuclease in the CHEF-RFA procedure, all outbreak 
isolates again shared a DNA fragment pattern that differed from the patterns of the control 
isolates (data not shown). With Sfil, the coefficient of similarity ranged from 0.95 to 1.0 for all 
outbreak isolates and from 0.30 to 0.89 for unrelated controls. With Eagl, the coefficient of 
similarity was 1.0 for all outbreak isolates and ranged from 0.00 to 0.92 for unrelated controls. 
Results were similar with Sacll and Nael, although the differences were not as easily visualized. 
Isoenzyme typing discriminated between the two groups of C. tropicalis isolates in the same 
manner as did CHEF-RFA (figure 3). Of the enzymes tested, several showed no heterogeneity. 
Both acid and alkaline phosphatase activities had the same patterns on gels, but the former 
gave better staining results. The isoenzyme profile used for determining the type was based 
on the patterns of enzymes that demonstrated heterogeneity; these were the a-glucosidases, 
ß-glucosidases, esterases, superoxide dismutases, acid phosphatases, and glucose-6-
phosphate dehydrogenases (table 1). 
Chapter 2 
• G l u c o s i d a s e Esterase SOD 
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
- G l u c o s i d a s e Acid phosphatase G-6-PDH 
• * · * * 
1 2 3 4 5 6 7 8 910 1 2 3 4 5 6 7 8 9 1 0 1 2 3 4 5 6 7 8 9 1 0 
ШШЦ-Щ' ill" <№i Ш іііі 
Figure 3. Isoenzymes of оиіБгеак and unrelated conlrot isolates of С tropicalis. Lanes I-4 show С tropicalis control isolates U4. L'I. U2. 
and U3. respectively: lanes 5-9. outbreak isolates E4-E8: and lane 10. С albicarti; control G-6-PDH = glucose-6-phosphate dehydroge­
nase. SOD = superoxide dismutase. Asterisks indicate lanes where enzyme migration of а С tropicalis control isolale differs clearls from 
lhat of the outbreak isolates 
Discussion 
C. tropicalis ¡s becoming increasingly common as an etiologic agent of nosocomial infections 
in neutropenic patients, patients undergoing surgery, and patients with indwelling catheters 
81128
. For an assessment of the importance of features such as person-to-person transmission 
among patients and medical and nursing staff, it is necessary to develop reliable and highly 
discriminatory typing procedures suitable for use with this species. Although the authors of 
some early studies reported strain heterogeneity determined by RFA 184 or isoenzyme profiles 
209
, they did not analyze a panel of epidmiologically characterized isolates: thus, the 
usefulness of methods for evaluating outbreaks has not been determined. Here we have used 
CHEF gel electroporetic karyotyping, CHEF-RFA, and isoenzyme analysis to establish molecular 
types for C. tropicalis, and we have compared our findings with those reported recently 
when RFA, coupled with computerized image analysis, was applied to the same panel of 
isolates 39. While conventional CHEF gel electrophoresis did not prove to be a useful 
molecular typing procedure, the types defined by both isoenzyme profile and CHEF-RFA are 
in concordance with the types obtained by RFA. These data further confirm the 
epidemiological link (reported by Isenberg et al.71) between isolates from the scrub nurse and 
those from the patients' wounds. 
Karyotypes established by CHEF-gel electrophoresis seem to constitute a reliable molecular 
typing tool for discrimination among strains of C. albicans l05113.122.14e.21e_ similarly, it seems tha t 
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Comparison of typing systems for Candida species 
karyotyping will be useful for discriminating among strains of other species, including 
C. guilliermondii, С. kefyr {Candida pseudotroptcalis), C. glabrata {Torulopsis g/abrato), and 
С lusitaniae 71 m l<e. In an extensive survey of clinical isolates of yeasts, Pittet and associates 
showed the value of electrophoretic karyotypes in the analysis of infections caused by 
C. albicans and many other species M e; notably, however, there appears to be only limited 
heterogeneity associated with the electrophoretic karyotypes of C. tropicalis122 M 8. 
In the current study, we were unable to discriminate between epidemiologically related and 
unrelated isolates of C. tropicalis by standard CHEF gel electrophoresis alone. Coupled with 
the results of Pittet and colleagues 148, our findings indicate that karyotyping by conventional 
CHEF gel electrophoresis is inadequate as a procedure for delineating strains of C. tropicalis. 
50 Only with very long and complex pulsed-field gel electrophoresis protocols have the 
chromosomes of С tropicalis been resolved to a reasonable extent 5 1 2 0 ' . For a single alkane-
m 
^ utilizing strain of С tropicalis, electrophoresis had to be performed for 100-166 hours, and 
it 
3 even then the larger chromosomes were not very well resolved. Compared with such lengthy 
о 
to electrophoretic runs, the 24-hour separation of chromosome fragments with CHEF-RFA was 
~< 
S. extremely convenient. Heterogeneities in CHEF-RFA patterns allowed us to differentiate 
·< 
•i among strains of С tropicalis easily. As a result, the epidemiologically related isolates could 
^ be grouped. The advantages of CHEF-RFA over conventional RFA he in its reproducibility and 
о the ready interpretation of the more limited pattern of bands. The limits to the discriminatory 
a power of this procedure have not been fully explored, and the resolution of DNA fragments 
о 
by CHEF-RFA is likely to be improved as a result of the use of different conditions during 
electrophoresis and possibly the use of other restriction endonucleases. 
There was complete concordance between the types observed by RFA 39 and the types 
defined by CHEF-RFA and isoenzyme profiles However, other researchers have reported 
differences in discriminatory power between electrophoretic karyotyping and other methods 
used for typing Candida species. Merz et al described a greater discriminatory power of 
electrophoretic karyotypes than of isoenzyme profiles in the molecular typing of C. lusitaniae 
'
u
. Similarly, Vazquez and co-workers, who evaluated 35 isolates of С albicans from 20 
patients, claimed that karyotyping by CHEF gel electrophoresis had a greater discriminatory 
power than RFA; they found 23 distinct electrophoretic karyotypes but only 17 distinct RFA 
types 2 ' 8 . The epidemiological significance of the types described by Vazquez et al. is far from 
clear, however. We consider it advisable, whenever possible, to compare typing procedures 
in tests with isolates whose genetic and epidemiological relationships have been well 
defined. Such a panel of isolates was provided by the outbreak of C. tropicalis infection 
described by Isenberg et a l . 7 I , and the genetic relationships of the isolates in this panel have 
been confirmed by RFA coupled to computerized image analysis 3'. Therefore, we are 
confident that both the isoenzyme profile and the CHEF-RFA pattern could be used to 
delineate strains in epidemiological investigations of С tropicalis 
Chapter 2 
White none of the three typing methods tor C. tropicalis - RFA, CHEF-RFA, and isoenzyme 
analysis - can be considered routine for the clinical laboratory, each is fairly easy to perform. 
Isoenzymes are somewhat inconvenient in requiring both a large quantity of yeast for culture 
and several different chromogenic reagents, buffers, and concentrations of acrylamide in 
the Polyacrylamide gels. In addition, a certain amount of run-to-run variation can lead to 
difficulties in the comparison of isoenzyme patterns from different gels. Furthermore, while 
isoenzyme profiles seem excellent markers that allow discrimination among species ' 4 2 0', they 
are not as discriminatory as either electrophoretic karyotypes l u or RFA pattterns ' 6 1 0 3 for 
delineating strains of Candida species other than C. tropicalis. In contrast to isoenzyme 
analysis, both RFA and CHEF-RFA require few reagents, and the type of any isolate is based 
on a pattern of DNA fragments resolved within a single gel. Zhang et al. 25° have cited the 51 
investigation of Mycobacterium tuberculosis isolates by pulsed-field gel electrophoresis in 
m 
combination with chromosome digestion by rare-cutting restriction enzymes: likewise, CHEF- 0. 
CD 
RFA provides a convenient tool for epidemiological studies on yeasts. Once conditions have § 
о 
been established for investigating a species, the procedure is simple to perform. The clear <Q 
о 
resolution of DNA fragments may make CHEF-RFA preferable to RFA when the interpretation ^ 
of fragment patterns is easiest by means of a computerized image analysis unit 3 9 . Regardless о 
of the method chosen, meaningful epidemiological studies of C. tropicalis should prove " 
о 
feasible. ^ 
Q. 
о 
Comparison of typing syslems for Candida species 
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Chapter 2.2 
Epidemiologic genotyping of Candida species by pulsed-
field gel electrophoresis and PCR-fingerprinting 
Andreas Voss, Michael A. Pfaller, Richard J. Holiis, Willem J.G. Melchers, and 
Jacques F.G.M. Meis. 
submitted 
Abstract 
Molecular typing methods are increasingly applied for studies where the interpretation of 
data essentially relies on the typing results rather than epidemiological data. In this situation, 
the discriminatory power (ability to identify differences among epidemiologlcally unrelated 
strains) of the typing method is important in allowing and drawing valid conclusions. By 
applying PCR-fingerprinting, electrophoretic karyotyping, and restriction fragment endo-
nuclease analysis using standard restriction enzymes and primers proven to be useful In 
previous studies, we evaluated whether the use of multiple genotyping methods is sufficient to 
delineate known unrelated strains among seven Candida species. All three methods 
identified individual genotypes for each of the seven Candida species studied, however 
optimal strain delineation required the combined use of all three typing methods and was 
observed only with the С albicans and C. tropicalis isolates tested. 
Introduction 
The increasing incidence of nosocomial candidosis has become a serious clinical problem 
13 1« 150 This trend is paralleled by an increasing need to define the pathogenesis and the 
mode of transmission of invasive candidosis, in order to direct preventive measurements. 
Epidemiological typing of microorganisms is frequently used to supplement a careful 
epidemiological investigation, such as the investigation of outbreaks of infection due to 
different Candida species '2112427394673134 ш ιβό 192225249. Recently, genotyping methods have 
been applied to studies on pathogenesis 158214222
 0 r antifungal resistance development 
11 119 159 172
 w h e r e the interpretation of the data relies heavily on the typing results In this 
situation investigators must be sure that the typing method employed, either singly or in 
combination, has the ability (discriminative power) to identify differences among 
epidemiologically unrelated strains Most of these so-called "molecular epidemiology" 
studies depend upon DNA-based typing techniques M 6 ' " 2 1 3 7 1 3 9 ; and under most circum-
Molecular epidemiology and pathogenesis 
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stances the rationale for the epidemiological typing boils down to "whether two or more 
strains of a given species are the same or different" m . 
Various molecular epidemiologic typing methods such as restriction endonuclease analysis of 
genomic DNA ise івз2іб_ pcR-fingerprintmg 9 5 2 l < , Southern hybridization analysis " e i o e w 
electrophoretic karyotyping using pulsed-field gel electrophoresis (PFGE) I<M222_
 a n c j 
¡mmunoblot fingerprinting 2 6 β β have been applied to studies of Candida species. Further­
more, Polyacrylamide gel electrophoresis (PAGE) ее 214
 a n c j multilocus enzyme electropho­
resis ' 3 have been used successfully in Candida typing. Applied to specific situations, each of 
these methods has advantages and disadvantages. Two methods, PCR-fingerprinting and 
54 restriction endonuclease analysis of genomic-DNA (REAG) using PFGE, are frequently used to 
type Candida spp., due primarily to ease of performance and discriminatory power, 
m 
5^  respectively. Previous studies using PCR-fingerprinting and REAG to identify strains of 
Φ 
3 С. albicans and C. tropicalis, respectively, documented a high level of discrimination ^214 
о 
S For future epidemiological investigations it is likely that these methods will be applied to other 
-< 
2. species of Candida, possibly without re-evaluating the discriminatory power. 
We evaluated whether these methods are sufficient to discriminate among epidemiologically 
Φ 
3 
η 
о unrelated isolates of other Candida species, or if detailed information on the primers/enzymes 
â used for PCR-fingerprinting and PFGE are necessary to achieve a sufficiently high 
о 
5 discriminative power. 
Φ 
η 
5 
3
 Materials and Methods 
Isolates. We chose four epidemiologically unrelated isolates from each of seven Candida 
species, namely C. albicans, C. tropicalis, С. (cruse/, С. glabrata, С. parapsilosis, С pseudo-
tropicalis, and C. guillermondii. All of these (reference) strains originated from the Centraal 
Bureau voor Schimmelcultures (CBS), Baarn, The Netherlands. Isolates were c o d e d and were 
sent as Candida spp. for typing in laboratories that were blinded to their origin and 
identification. 
PFGE Molecular typing and DNA preparation. Candida strains were karyotyped by contour-
c lamped homogeneous electric field (CHEF) electrophoresis of genomic DNA 3', and also 
typed by restriction endonuclease analysis of genomic DNA (REAG) after digestion with the 
restriction endonuclease SssHII "'. The DNA for the molecular typing was prepared as 
described earlier2 2 2. 
CHEF karyotyping. Electrophoresis was performed with a CHEF-DRII pulsed-field 
electrophoretic system (BioRad) in 0.7% agarose gel (SeaKem GTG) - 0.5 χ lOOmM Tris (pH 9.5), 
100 mM boric acid, and 1.0 mM EDTA at 150V and 13°C. The pulse interval was 120 seconds 
for 24 hours followed by 240 seconds for 36 hours. Saccharomyces cerevisiae 
Chapter 2 
chromosome/DNA molecular weight markers (BioRad) were included in each gel as 
standard After electrophoresis, the gels were stained with ethidium bromide, illuminated 
under ultraviolet light, and photographed with Polaroid 107C film (Polaroid, Cambridge, 
MA,USA) 
REAG For the restriction endonuclease analysis of genomic DNA (REAG), agarose inserts 
containing chromosome-sized DNA were prepared as described above and placed into 100 
mM Tns-HCI (pH 8 0) containing 5 mM magnesium chloride Agarose inserts were washed 
twice and placed in 100 μ ι of buffer containing 20 U of BssH II restriction endonuclease (New 
England Biolabs, Beverly, MA,USA) Overnight digestion was performed as described by the 
manufacturer 
Electrophoresis was performed with a CHEF-DRII pulsed-field electrophoretic system (BioRad) 55 
in 1 0% agarose gel (SeaKem GTG) - 0 5 χ TBE buffer at 200V and 13°C The pulse interval was 
m 
ramped from 10 to 90 seconds over 24 hours The 48 5-kb lambda DNA ladder (BioRad) was Q. 
included in each gel as molecular weight standard After electrophoresis, gels were stained § 
0 
with ethidium bromide, illuminated under ultraviolet light, and photographed with Polaroid <§ 
107C film (Polaroid) 3Γ 
PCR DNA extraction All Candida isolates were grown in Sabauroud glucose broth » 
Genomic DNA for RAPD was prepared as follows cultures were centnfuged and washed " 
Q 
twice in phosphate buffered saline, resuspended in 250 μΙ STET buffer ( 233 mM sucrose, 50 ¿ 
mM TRIS-HCI pH 8 0 20 mM EDTA, 5% Triton X-100) Lysozyme was added to a final ° 
concentration of 1 7 mg/ml The suspension was incubated at room temp for 5 mm, heated g 
at 100°C for 1 mm and put on ice for another 2 mm In succession sodium dodecyl sulphate g 
and proteinase К was a d d e d to the solution to a final concentration of 0 3% and 0 5 mg/ml 
respectively, which was then incubated at 55°C for 2 hours Following extraction with phenol 
0 03 mg/ml RNAse A was a d d e d and the mixture was incubated at 37°C for 20 mm The 
solution was extracted successively with phenol/ chlorophorm/isoamyl-alcohol (25 24 1) and 
chlorophorm/isoamyl-alcohol (24 1 ) DNA was precipitated overnight and resuspended in 
100 μΙ of distilled water An alliquot was electrophoresed in a 1% agarose gel containing 0 1 
pg/ml ethidium bromide to estimate the DNA yield and verify DNA integrity 
RAPD analysis PCR fingerprinting of Candida DNA (50 ng) was performed in a 50 μΙ reaction 
volume containing 75 mM Tns-HCI (pH 9 0), 2 5 mM MgCb, 20 mM (NH4)2SO< 0 01% Tween-20, 
0 2 mM dNTPs each 50 pmol of primer 1283 (5'-GCGATCCCCA-3') and 0 2 U of Taq DNA 
polymerase (Thermoperfectplus DNA polymerase,Integro, Zaandam, The Netherlands) A 
Perkin-Elmer 9600 thermocycler was used for amplification The cycling program run was 4 
cycles of 94 °C for 5 mm 36 °C for 5 mm 72°C for 5 mm followed by 30 cycles of 94°C for 1 
mm 36°C for 1 mm 72 °C for 2 mm and a 10 mm incubation at 72 °C Amplified DNA (5 μΙ) was 
separated by electrophoresis in 1 5 % agarose gels and visualized by ethidium bromide 
staining (0 1 μg/ml) A molecular size marker (100 bp ladder Pharmacia, Woerden, The 
Netherlands) was used for reference 
Comparison of typing systems for Candida species 
Analysis Photographs of ethidium bromide-stained gels were analyzed to detect similarities 
and differences in banding patterns. Isolates were considered "identical" when all of the 
bands matched; "similar" when > 95% but less than 100% of the bands matched, and 
"different" with less than 95% matching bands. 
Results 
Genotyping results as determined by PFGE karyotyping, REAG, and PCR fingerprinting are 
described in table 1. 
Table 1: Genotypes of 
BssH fl macro 
fingerprinting. 
seven different Candide 
restriction analysis with 
species determined by karyotyping 
pulsed-field gel electrophoresis a n d 
and 
PCR 
Strain 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
Species 
C. albicans 
C. krusei 
C. glabrata 
C. tropicalis 
С. parapsilosis 
С. pseudotropicalis 
С. guillermondii 
Reference 
CBS 562 
АТСС 10231 
АТСС 24433 
AZN 3982 
CBS 6891 
АТСС 62069 
CBS 573 
AZN 3962 
CBS 1518 
CBS 860 
CBS 7307 
AZN 3944 
CBS 8072 
CBS 6320 
CBS 6957 
AZN 3672 
CBS 1954 
CBS 6318 
CBS 2194 
AZN 3526 
CBS 2234 
CBS 1561 
CBS 2231 
AZN 402 
CBS 6316 
CBS 2021 
CBS 7099 
AZN 2102 
Genotype according to*: 
Karyotype 
A 
В 
С 
D 
E 
F 
E 
E 
G 
G' 
H 
1 
J 
J 
к 
J 
L 
L' 
L" 
L 
M 
N 
M 
N' 
Ρ 
Ρ' 
Ρ' 
Ρ 
REAG 
1 
2 
3 
4 
5 
6 
5 
7 
8 
8 
8' 
9 
10 
11 
12 
13 
14 
14 
14' 
14' 
15 
16 
15' 
16' 
17 
17' 
17' 
17 
PCR 
I 
II 
I 
III 
IV 
IV 
IV' 
IV' 
ν 
V' 
V' 
ν 
VI 
VI 
VII 
VIH 
IX 
IX 
IX 
IX' 
χ 
Χ' 
χ 
χ 
XI 
XI 
XI 
XI 
overall 
α 
b 
с 
d 
e 
f 
e 
Я 
h 
h 
i 
I 
k 
I 
m 
η 
о 
о 
о' 
о' 
Ρ 
q 
Ρ 
q 
г 
г 
г 
г 
CBS strains = Reference strains from the Centraal Bureau voor Schimmelcultures, Baarn, The Netherlands 
AZN strains = Clinical strains from the University Hospital Nijmegen, strain identity confirmed by CBS 
REAG = restriction endonuclease analysis of genomic-DNA pattern 
PCR = PCR-fingerprinting pattern using BssH II 
* similar but not identical pattern (share 95-99% of bands) are denoted as ' or " 
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Overall 18 different genotypes were determined among the 28 unique Candida strains; 16 by 
karyotyping, 17 by REAG, and 11 by PCR-fingerprinting, respectively. All typing methods 
showed individual genotypes for each of the seven Candida species evaluated and were 
able to identify the four different C. albicans strains tested. C. tropicalis was the only other 
Candida species in which the use of one or more typing methods was able to identify all four 
strains. Combining the results of all three methods resulted in the identification of three of the 
four unique strains of C. krusei and С glabrata, and two of the four strains of 
C. pseudotropicalis. None of the three typing methods alone or in combination was able to 
discriminate among the С parapsilosis and C. guillermondiï reference strains. Of the three 
typing methods, PCR-fingerprinting was the least discriminative method. 
Discussion 
57 
•g 
a 
3 
In general, epidemiologic typing systems are used to study microbial population genetics, the §• 
(Q 
pathogenesis or surveillance of infectious diseases, and the investigation of outbreaks. Until ^ 
recently no common definitions and guidelines on performance criteria, such as typeability, •< 
ST 
reproducibility, stability, discriminatory power, test population, and epidemiologic 3 
o' 
concordance were in place. The lack of such performance criteria made a standardized £> 
interpretation of epidemiological typing results difficult and may have contributed to the & 
о 
suggestion, that no single typing method is sufficient to fulfill the above mentioned tasks, and j 
n> 
that most epidemiologic investigations may require more than one method for optimal strain 0. 
о 
delineation. 
Recently, a European consensus guideline for appropriate use and evaluation of microbial 
epidemiologic typing systems was published 207. The authors suggest that the discriminatory 
power should be >0.95, thereby complying with the conventional 5% level of acceptable 
probability of type I error. We hypothesized that these standards will not be matched by 
"today's practice", the use of two independent DNA-based methods. This practice might be 
insufficient to delineate without fail epidemiologically related and unrelated strains of 
Candida species. To comply with the above mentioned standards, additional validation of 
the primers/enzymes used are probably needed, for each species of Candida tested. 
Various molecular epidemiologic typing methods have been used to delineate strains within 
Candida species <26.4e.95.1 o<. 1 oe. 1 se. 1 вэ.19?.214.21ΐ.222 Karyotyping by PFGE was shown to be a useful 
molecular typing tool to identify different С albicans strains 113.122.ue.21e. Similarly, karyotyping 
was shown to provide some discrimination among strains of C. pseudolropicalis, C. glabrata, 
and C. lusitaniae "«-ue, an observation we could not confirm in the present study. Among the 
seven Candida species evaluated, karyotyping was only able to discriminate all four 
C. albicans strains and three of the four C. glabrata reference strains tested. The inability of 
this typing method to reliably delineate strains among all species of Candida was shown 
earlier for C. tropicalis * '. 
Our study shows that with the exception of С albicans and C. tropicalis even the use of 
several different genotyping methods in combination may indicate identity among 
epidemiologically unrelated strains of non-C. albicans species. The fact that several of the 
isolates showed an identical typing pattern clearly increases the chance for invalid 
epidemiological conclusions. 
In order to evaluate the resolution of their PCR assay, van Belkum et al. 2 U reviewed 
genotyping studies on a panel of 21 C. albicans reference isolates. Despite the use of PFGE 
karyotyping, RFLP, Southern-blot hybridization, and 8 different PCR assays, only 13 different 
types were found. The general inability of all typing systems to delineate among different 
epidemiologically unrelated strains of С albicans was not further discussed. The inability of 
58 similar typing methods in the present study to reliably identify unrelated strains of 
non-C. albicans species might be due to a limited genetic diversity of some Candida species, 
m 
5^  or may just be an expression of the fact that molecular epidemiological studies done so far 
(0 
3 do not reach the discriminative ability that is asked for in the recent standard 207. 
о 
a Furthermore, this observation is an indication that the number of isolates used to evaluate the 
-< 
S, discriminative power is of utmost importance. 
• < 
~ Typing assays that are able to delineate a certain Candida species, may not be used blindly 
^ for other species of that genus. In addition to the recent standardized definitions and 
о performance criteria, and the urge to use at least two different (geno) typing systems, 
о. species-specific restriction enzymes and primers, which were validated using a large number 
a 
5 of different strains, should be used. Using the normal statistical threshold of 0.05 we should 
о 
2- expect that one or more typing assays used to answer important epidemiologic and 
pathogenetic questions, should delineate 19 of 20 reference strains. This level of 
discrimination certainly has not been reached in a fair proportion of the published studies 
using molecular typing. Despite recent progress to standardize and validate typing systems, 
the available typing methods still need further attention, especially to increase the 
discriminative power 
Chapter 2 
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Chapter 3.1 
Investigation of the sequence of colonization and candidemia in 
nonneutropenic patients 
Andreas Voss, Richard J. Hollis, Michael A Pfaller, Richard Ρ Wenzel, and Bradley N. 
Doebbe/mg. 
Journal of Clinical Microbiology, 1994;32:975-980 
Abstract 61 
m 
Among neutropenic patients with hematologic malignancies, candidemia has been shown to a 
CD 
arise typically from autoinfection after colonization. In patients without neutropenia, we § 
Ö 
examined the similarities of strains colonizing or infecting various body sites and those <Q 
о 
subsequently causing Candida bloodstream infections. Strain similarity was examined by ~ 
~< 
karyotyping and restriction endonuclease analysis of genomic DNA (REAG) by using two a 
restriction enzymes (SrTI and flssHII). The banding patterns of 42 isolates from 19 patients were Д 
independently evaluated in a blinded fashion by three observers. The interobserver reliability э 
measured with a generalized kappa statistic was 0.59 for karyotyping, 0.48 for REAG with Sf¡\, о 
and 0.88 for REAG with BssHII (P < 0.001 for each). REAG classified the initial colonizing or n> 
infecting isolate and subsequent blood isolates as identical in 14 patients (84%). The mean § 
duration of colonization or infection prior to a positive blood culture was 5 and 23 days in 
patients infected with related and unrelated isolates, respectively (P = 0.14; 95% confidence 
interval = -14.5 to 50.5). Karyotyping results matched the REAG results for isolates from 14 of 
the 19 patients (74%). In patients infected with identical isolates, the initial isolate was most 
frequently recovered from the urine (n = 5) or vascular catheter tips (n = 4). In the five subjects 
with organisms showing disparate results between the methods, karyotyping revealed 
different banding patterns, whereas REAG suggested that the isolates were identical. Candida 
colonization or infection with an identical strain frequently precedes bloodstream infection in 
nonneutropenic patients. Future studies should evaluate whether patients at high risk for 
candidemia and who have vascular catheter or urine samples that are positive for a Candida 
on culture should be treated empirically. 
Introduction 
In recent years, Candida spp. have emerged as important nosocomial pathogens. Between 
1978 and 1984, the incidence of Candida bloodstream infections increased by 3- to 10-fold 
30 48 Over the past decade, the incidence of Candida bloodstream infections increased by 
Molecular epidemiology and pathogenesis 
two- to fivefold in U.S. teaching hospitals and by one- to fourfold in nonteaching hospitals8 1 8 3. 
Candidemia occurs most frequently in immunocompromised patients with an underlying 
malignancy or hematologic disorder , l s " 7 , severely ill burn patients, and patients in surgical 
and neonatal intensive care units 6 2 3 2 9 | 5 ί " 7 203. Therefore, the incidence of candidemia is 
highest in tertiary-care referral hospitals. At our center, the incidence was 8.5/10.000 
admissions in 1992. Candidemia is associated with a 57% crude and a 38% attributable 
(direct) mortality 237 
The clinical importance of Candida colonization at different body sites has been 
controversial. For example, some have argued whether strains colonizing the urine or stool 
subsequently cause candidemia. Among hematologic malignancy and bone marrow 
62 transplantation patients, Reagan et al. Ι 5 β demonstrated that colonizing and subsequently 
infecting strains of Candida spp. were identical in 94% of patients In a carefully conducted 
m 
2 case-control study, four independent risk factors for candidemia were identified after 
Φ 3 accounting for underlying disease, colonization by Candida species at various body sites, 
о 
со prior exposure to hemodialysis, central intravascular catheters, and previous exposure to 
2, antibiotics 23B. Relatively little, however, is known about the molecular epidemiology of 
• < 
~ antecedent colonization and candidemia in nonneutropenic patients. 
ñ Since May 1987, our laboratory has routinely banked all Candida isolates from the 
о bloodstream as well as any available Candida isolate from other clinical sites in the same 
о. patient. The purpose of the study described here was to evaluate the similarity of Candida 
о 
5 bloodstream isolates and prior colonization or infecting isolates in nonneutropenic patients. 
Φ 2. Fingerprinting of the organisms was performed by karyotyping and restriction endonuclease 
о 
analysis of genomic DNA (REAG) by using contour-clamped homogenous electrophoretic 
field (CHEF) electrophoresis 
Materials and Methods 
Hospitals and patients. The University of Iowa Hospitals and Clinics is a 900-bed teaching 
hospital and tertiary-care referral center, with approximately 200 beds designated for 
intensive care. Patients with Candida infections were identified retrospectively by reviewing 
the microbiology reports for isolates banked from May 1987 to July 1992. Neutropenic 
hematology-oncology and bone marrow transplant patients and those without a previous 
sample from another site that was positive for Candida species on culture before their blood 
sample was positive on culture were excluded from the study. During the study period, all 
Candida isolates were stored in sterile distilled water at ambient temperature Isolates from 
patients included in the current study were retrieved from this isolate bank and were 
identified to the species level by using the API 20C system (Analytab Products, Plainview, 
NY) 
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Molecular typing and DNA preparation. Ten colonies (> 1 mm) of each Candida isolate 
from 48-h cultures on Sabouraud agar plates were incubated overnight at 37°C in 10 ml of 
YEPD broth (yeast extract, 10 g/liter; peptone, 10 g/liter; and D-glucose, 20 g/liter). The cells 
were packed by centrifugation (1,000 χ g for 15 min), washed in sterile distilled water, and 
introduced into preweighed Eppendorf tubes. The pellets were suspended in 1 volume of 50 
mM sodium EDTA (50E; pH 8.0). The cell titer was normalized by adding the volume (in 
microliters) equal to the weight of the cells (in milligrams). A 173-ml of lyticase (L5263; Sigma 
Chemical, St. Louis, Mo.), and 295 ml of 2% agarose (SeaPlaque GTG; FMC BioProducts, 
Rockland, Maine) that was previously melted and kept liquid at 56°C. Aliquots were placed in 
forms (Bio-Rad, Hercules, Calif.) that were incubated for 2 h at 37°C. The inserts were removed 
from the forms and were placed in 2 ml of a buffer of 10 mM Tris-HCI (pH 7.5), 400 mM EDTA, 63 
1% Sarkosyl, 0.750 mg of proteinase К per ml (protease type XXVII; Sigma) and incubated 
m 
overnight at 50°C. The inserts were washed six times in 50E and were stored at 5°C until use. 5. 
Φ 
CHEF karyotyping. Electrophoresis was performed with a CHEF-DRII pulsed-field § 
о 
electrophoretic system (Bio-Rad) in 0.7% agarose (SeaKem GTG agarose; FMC BioProducts)- <Q 
0 5x 100 mM Tris (pH 8.5J-100 mM boric acid-l.OmM EDTA (TBE buffer) at 13°C and 150 V. The 7 
pulse interval was 120 s for 24 h and then 240 s for 36 h. Saccharomyces cerevisiae Φ 
chromosome DNA molecular weight markers (Bio-Rad) were included in each gel as ¡2 
a 
standards. After electrophoresis, the gels were stained with ethidium bromide, illuminated ^ 
Q. 
with UV light, and photographed. о 
REAG. For restriction endonuclease digestion, agarose inserts containing chromosome-sized £ 
DNA were prepared as described above and were placed into 100 mM Tris-HCI (pH 8.0) § 
containing 5 mM magnesium chloride. After two washes with the buffer, the agarose inserts 
were digested overnight with 20 U of Sfi\ or BssHII (New England Biolabs, Beverly, Mass), as 
recommended by the manufacturer. 
Electrophoresis was performed with a CHEF-DRII pulsed field electrophoretic system (Bio-Rad). 
Electrophoresis was performed in 1.0% agarose gel (SeaKem GTGJ-0.5 χ TBE at 13°C and 200 
V. The pulse interval was ramped from 5 to 90 s over 24 h. The 48.5-kb bacteriophage lambda 
DNA ladders (Bio-Rad) were included in each gel as molecular size standards. After 
electrophoresis, the gels were stained with ethidium bromide, illuminated under UV light, and 
photographed. 
Analysis. Three observers, blinded to the origin of the isolate and the results of the other 
observers, examined the photographs of the ethidium bromide-stained gels to detect 
similarities and differences in banding patterns. All bands had to match exactly to classify 
isolates as identical; any difference in a major or a minor band was considered important. 
Banding patterns with >95% but less than 100% of the bands matching were termed "similar." 
Isolates with less than 95% of bands matching were considered different. 
Molecular epidemiology and pathogenesis 
Interobserver reliability was calculated with the generalized kappa statistic for measurement 
of agreement 7*7. Means were compared with a t-test for independent samples after 
evaluation for equality of the variances by Levene's test. Alpha was set at 0.05, and all Ρ 
values are two-tailed 
Results 
During the study period, 107 patients whose blood was positive for Candida spp. on culture 
were identified; 19 patients (17.8%) met the inclusion criteria. The other patients were 
neutropenic and had a hematologic malignancy or were undergoing bone marrow 
64 transplantation (40.2%), did not have positive cultures of samples from another site before 
their positive blood culture (34.6%), or had different fungal species isolated from their blood 
•g 
a and another body site previously (7.5%). Therefore, 42 Candida strains (C. albicans [n = 35], 
§ C. tropicalis [η = 5], С. parapsilosis [η = 2]) from 19 patients (Table 1) were available for 
(Q molecular typing. The 19 patients represented 30% of the total number of nonneutropenic 
37 patients with candidemia during the study period. 
• < 
if The underlying diseases of the 19 patients included 6 (31%) with solid tumors, 1 (5%) with acute 
ñ lymphocytic leukemia prior to treatment, and 11 (58%) with prior surgery involving the 
η § gastrointestinal tract. Diabetes mellitus or prior antibiotic treatment were present in 16 and 
g 
a.' 89% of the study patients, respectively. None of the patients included in the study were 
2, neutropenic either prior to or at the time of candidemia. The interval between the isolation of 
~ Candida spp. from a blood culture and another body site previously ranged from 1 to 31 
days, with a mean of 7.8 days (median, 5 days). In patients in whom the isolate from a blood 
culture and isolates from other sites were identical by REAG, the interval between the 
isolations ranged from 1 to 11 days, with a mean of 5 days (median, 4 days). By contrast, 
nonidentical isolates from colonized or infected body sites occurred from 8 to 31 days earlier 
than the bloodstream isolate, with a mean of 23 days (median 30 days). This mean difference 
in time from positivity for a prior Candida isolate was not statistically significant (P = 0.14; 95% 
confidence interval about the difference = -14.5 to 50.5), although the power to detect a 
difference was low, given the relatively few subjects with nonidentical isolate pairs. In the 16 
patients with identical isolates from a blood culture and another site, the urine (n = 5) and 
catheter tips (n = 4) were the most frequent prior sites. Specimens from the respiratory tract (n 
= 1) and remote (> 30 days) tissue biopsy specimens (n = 2) were the sources of the initial 
isolates among the three patients with nonidentical isolate pairs by REAG. 
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Table î : Clinical characteristics of study patients ________—_ 
Patient 
code 
A 
В 
С 
D 
E 
F 
G 
H 
1 
J 
К 
L 
M 
N 
О 
Ρ 
Q 
R 
S 
Age 
(yr) 
36 
4 
27 
68 
87 
58 
52 
76 
78 
27 
56 
61 
73 
46 
52 
70 
80 
60 
69 
Sexa 
M 
F 
M 
F 
M 
F 
F 
M 
F 
M 
F 
M 
M 
F 
F 
M 
M 
F 
M 
Underlying disease0 
Pancreas and kidney transplant, 
DM 
Acute lymphocytic leukemia 
Motor vehicle accident, burn 
injury (52% BSA) 
Transoral odontoid resection 
and tracheostomy 
Motor vehicle accident, intra­
ventricular hemorrhage 
Ovarian neoplasma, DM 
Cervical carcinoma, post radia­
tion cystitis and enteritis 
Head and neck cancer, intraspi­
nal abscess 
Amyloidosis, stroke 
Burn injury (90% BSA) 
Biliary tract obstruction, pan­
creatitis 
Pancreatitis 
Aortic valve stenosis, CABG, DM 
Gl surgery, urinary diversion 
Status post-GI surgery, myocar­
dial infarction 
Coronary artery disease 
Bladder carcinoma, cystectomy, 
with ileal conduit 
Cervical carcinoma, status post-
pelvic exoneration 
Status post-oropharyngeal car­
cinoma, dysphagia 
Species 
С albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. albicans 
C. tropicalis 
С. parapsilosis 
С. albicans 
° M: males, F; females 
ь
 BSA: body surface area, DM: diabetes mellitus, CABG: coronary artery bypass graft, Gl: gastrointestinal 
In the analysis of the fingerprint patterns of the isolates, a high ¡nterobserver reliability was 
observed; the generalized kappa statistic was 0.59 for karyotyping, 0.84 for REAG with Sfil, and 
0.88 for REAG with BssHII ( < 0.001 for each). The results of the overall interpretations (consensus 
call of the three observers) are given in Table 2. Overall, the method revealed 20 unique 
karyotypes. The karyotype banding patterns of initial site and subsequent bloodstream 
isolates (Fig. 1) were identical in 11 of 19 (57.9%) patients. In eight patients infected with either 
С albicans (n = 7) or C. parapsilosis (n = 1), the karyotypes of the paired isolates did not 
match. 
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Table 2: Results of karyotyping and REAG of isolates from a blood culture and other 
body sites 
Patient 
c o d e 
A 
В 
С 
D 
E 
F 
G 
H 
1 
J 
к 
L 
M 
N 
О 
Ρ 
Q 
R 
S 
Isolate 
lane no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
Origin 
Blood 
Urine 
B l o o d 
Stool 
B lood 
T r a c h e a l 
C a t h e t e r 
B lood 
Tissue 
Blood 
C a t h e t e r 
Blood 
Urine 
Urine 
Blood 
T r a c h e a l 
Blood 
Tissue 
Blood 
S p u t u m 
Blood 
Urine 
Blood 
Urine 
Blood 
Urine 
Bile 
B lood 
Pleura 
Blood 
T r a c h e a l 
Blood 
C a t h e t e r 
Blood 
C a t h e t e r 
Blood 
Ascites 
Ascites 
Blood 
Ascites 
Blood 
Ascites 
Interval 
(days) 
8 
4 
11 
1 
30 
1 
6 
1 
8 
31 
3 
1 
11 
5 
4 
8 
4 
2 
1 
8 
8 
3 
4 
Result by 
karyotyping 
a 
a 
b 
b 
a 
a 
a 
С 
d 
e 
f 
g 
g 
g 
h 
i 
i 
k 
k 
k 
1 
k 
k 
m 
η 
η 
η 
о 
Ρ 
k 
k 
k 
k 
k 
k 
q 
q 
a 
r 
s 
t 
t 
Result by REAG 
with STi Ia 
1 
1 
2 
2 
3 
3 
3 
4 
5 
6 
6 
7 
7 
7 
3 
8 
9 
10 
l i a 
l i a 
l i a 
l i a 
l i a 
l i a 
12 
12 
12 
13 
13 
14 
14 
11b 
11b 
l i a 
l i a 
15 
15 
15 
14 
14 
16 
16 
Result by REAG 
with BssH IIa 
1 
1 
2 
2 
3 
3 
3 
4 
5 
6 
6 
7 
7 
7 
3 
8 
9 
10 
11 
11 
12 
12 
11 
11 
13 
13 
13 
14 
14 
15 
15 
16a 
16a 
16b 
16b 
17 
17 
17 
18 
18 
19 
19 
a
 The difference denoted a or b are insufficient to classify the isolates as different (sharing 
<95% of bands) rather than similar (sharing >95% but < 100% of bands) 
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The relationships among isolates within a given patient determined by REAG (Fig. 2 and 3) 
were identical regardless of the restriction enzyme employed. The only difference observed in 
the REAG with the two different endonucleases was in the interpatient evaluation e.g., 
whether a specific banding pattern was classified as unique or shared with another patient. 
By the REAG method, isolates from the initial site and blood cultures were shown to be 
identical in 16 patients (84.2%). In three patients with С albicans infections, the paired isolates 
were different. Isolates from three patients (patients J, O, and P) were classified as identical 
with Sf/I, whereas their banding patterns after digestion with BssHII classified them as different. 
Thus, the REAG method identified 16 unique patterns after digestion with Sf/I and 19 after 
digestion with BssHII. 
Despite a similar number of unique karyotype patterns, the results matched the overall REAG 67 
results for only 14 of the 19 patients (74%). The isolates from five patients whose initial site and 
m 
blood isolates had different karyotypes appeared to be identical when REAG was done with a 
CD 
3 
o' 
о 
CO 
CD 
3 
o 
о 
a 
D 
Q 
Q 
3' 
ciT 
η 
δ' 
both enzymes (see Fig. 1 to 3, patients J and K). 
P! j G 
Isol S Ì15 16 
Π I I J IV i j L 
17 18(19 20|SJ21 22¡23 24¡S j25 26 27jC 
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. Щ ;¡i|j ^ J , 
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Trwwm mm**m 
FIG. 1. CHEF kaiyotype. Shown are the blood culture and other 
site isolates from patients G to L. Note that the patterns of isolates 
from patients I and L appear to be identical. The karyotype pattern 
denoted к (see Table 2) is seen in isolates 18, 19, 20, 22, and 23 of 
patients H, I, J, and K, respectively. Note that isolates 21 and 22 
(patient J) appeared to be different because of the spacing of the 
banding patterns. Abbreviations: Pt. patient; Isol, isolate number; S. 
molecular size standard: С. C'. alMcam control strain. 
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П О . 2. REAG with S fil. Shown are blood culture and other site 
isolates from patients G to L. Banding patterns of paired isolates of 
patients I to L appeared to be identical, including isolates from patients 
.1 and К with karyotype patterns that appeared to be different (see lig 
I ). The REAG pattern with S)i\ denoted 1 la (see Table 2) was shared 
In patients I. J. and K. Abbreviations: Pt. patient: Isol. isolate number: 
S. molecular size standard: C. C. albicans control strain. 
PI G H i t J ; К ! L 
Iwl S , 15 16 i 17 18¡19 20 i S i 21 2223 24 ¡ S : 25 26 2? С 
FIG. 3. REAG with B Í J H I I . Shown are blood culture and other site 
isolates from patients G to L. Banding patterns of paired isolates of 
subjects I to L appeared to be identical, as demonstrated previously by 
REAG with Sfil. The overall (within-subject) evaluation was identical 
lor REAG patterns with Sfil and BssHII. A difference between the two 
methods was seen only in the between-subject evaluation. Note that 
the banding patterns of isolates 21 and 22 (from patient J) do not 
match the banding patterns of isolates from patients J and K. as seen 
In REAG with Sfi\. Abbreviations: Pt. patient: Isol. isolate number: S. 
molécula 1 size standard: (". ( ulhicam control strain. 
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Discussion 
Rates of nosocomial bloodstream infections have increased markedly over the last decade, 
particularly because of the increased number of infections caused by coagulase-negative 
staphylococci. Candida spp., Staphylococcus aureus, and enterococci. In 1975, Candida 
spp. accounted for less than 3% of nosocomial bloodstream infections U7 but are currently 
responsible for approximately 10%237. Risk factors involved in the pathogenesis of candidemia 
have been identified in numerous studies ¿2729 75βι 100155147197203238. Case-control studies that 
use multivariate analysis to control for underlying diseases have convincingly demonstrated 
that colonization by Candida spp. at various body sites, prior exposure to hemodialysis, 
central intravascular catheters, previous exposure to antibiotics, and azotemia are 
independent risk factors for candidemia 27758123e until recently, it was suggested that 
candidemia arises more or less exclusively from autoinfection caused by colonizing organisms 
in the intestine. The availability of molecular typing methods has allowed investigators to 
confirm this hypothesis l 5 e ,85. Furthermore, unique strains colonize the patient, persist, and are 
frequently responsible for subsequent infection or relapse 4 8 2 0 5. Additionally, a number of 
documented outbreaks of Candida infections have highlighted the importance of 
transmission of Candida spp. from an exogenous source to the patient 273971123192225235239 
Our study, in which we used the REAG method for fingerprinting, demonstrated identical 
colonizing or infecting and blood culture isolates in the majority (84%) of the patients 
analyzed. Reagan et al. Ι5Θ found a slightly higher frequency of identical colonizing and 
infecting strains among hematologic malignancy and bone marrow transplant patients than 
we found in the current study. Importantly, the isolates compared by Reagan et al. Ι5Θ were 
routinely obtained as part of an ongoing surveillance program in severely 
immunocompromised patients. In contrast, most of the isolates from nonneutropenic patients 
in the present study were from cultures of clinical samples taken during sporadic 
epidemiologic surveillance or when an infection was suspected. However, our study 
population represented one-third of all nonneutropenic patients with candidemia during the 
study period. Furthermore, Reagan and colleagues 15θ reported that matching strains could 
be found even after an interval of up to 432 days. In our patients, the interval between a 
positive culture of a sample from another site an a positive blood sample culture was 
inversely related to the likelihood of finding identical colonizing and blood culture isolates. The 
fact that most of the isolates in our study were not obtained during ongoing surveillance may 
have created a selection bias that precluded a widespread generalization to all 
nonneutropenic patients. However, the high proportion of study patients with identical 
colonizing or infecting isolates prior to bloodstream infection supports the clinical view that 
the bloodstream infection frequently arises endogenously. 
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The difference ¡η interval (days) between the previous isolation of Candida species from a 
body site and a blood culture in patients in whom the blood culture and other site isolates 
were identical was approximately one-fifth of that in patients in whom the isolates were 
different. However, given the relatively small number of subjects, this difference did not reach 
statistical significance. The two patients whose tissue biopsy specimens were infected with 
С albicans were among three patients colonized or infected with a different strain prior to 
the development of candidemia. The extended time interval was long enough to allow 
recolonization and infection with a second strain, or the patients had been colonized with 
strains that were not isolated in the current study. Isolation of Candida species from tracheal 
secretions alone did not predict a subsequent bloodstream infection with the same strain. 
70 Among the patients with matching Candida strain pairs, the organisms were isolated initially 
most frequently from urine or vascular catheter tips. Since the isolates were not routinely 
m 
2 obtained as part of an ongoing surveillance program, it is difficult to draw firm conclusions 
Φ 
3 about this time interval. The observed differences in the interval between colonization or 
о 
¡о infection and subsequent bloodstream infection and initial isolation of Candida from a body 
~< 
2. site emphasize the fact that colonization of certain body sites (respiratory tract and remote 
·< 
¡s- tissue biopsy specimens) may infrequently result in candidemia with that same strain, despite 
^ long periods of follow-up. However, the presence of a Candida species at other sites (urine or 
о catheter tip) may be associated with subsequent candidemia within relatively short periods 
5. of time. 
о 
5 Patients with vascular catheters are at a significantly increased risk for fungal infections юогзв 
Φ 3- This may be due to the unique surface properties of Candida species, which allow it to 
о 
invade the host by attaching to plastic surfaces and evade the host immune system ю 1¿9. 
Some investigators argue that patients with catheter tip cultures positive for a Candida 
species require antifungal therapy, although this point is controversial. The safety and efficacy 
of early antifungal treatment of patients with a positive urine or vascular catheter tip culture 
and suspected fungal infections in preventing Candida species bloodstream infections could 
be evaluated prospectively. 
With four exceptions, each patient was infected by his or her own unique Candida strain, 
suggesting no clustering or transmission of a predominant strain The discriminative value of 
standard CHEF gel electrophoresis of C. albicans has been demonstrated l22,4S. However, 
data from two prior studies 4 ' l 2 2 suggest that karyotyping may be of limited value for the 
discrimination of С tropicalis isolates. The three typing methods used in the current study 
showed the identity of the С tropicalis strains in patients Q and S. Compared with the more 
easily interpretable banding patterns of REAG, the interpretation of standard CHEF gel 
electrophoresis may be difficult because of the fewer number of bands. In our study, the 
initial site and bloodstream isolates from five patients had different patterns by karyotyping, 
yet they had identical patterns after endonuclease digestion. The reason for this finding is 
unclear. 
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Both methods resulted in relatively high levels of agreement between observers, i.e., greater 
than that expected by chance alone. The kappa statistic demonstrated the greatest level of 
agreement between the observers for the two REAG methods. We would suggest the routine 
use of a statistical method, such as the kappa statistic, to compare different methods 
quantitatively in molecular typing studies. 
REAG appeared to be a reliable method for delineating strains of Candida spp. with high 
discriminatory abilities, regardless of whether BssHII or Sfi\ was used as the restriction enzyme. 
Since the cost per unit is considerably lower for Sf/I, this enzyme should be considered in 
typing situations in which a single restriction enzyme is needed. 
In summary, we found that in the majority of patients who develop disseminated Candida 
spp. infections, the initial colonizing or infection site and subsequent bloodstream isolates are 7 
identical. Furthermore, nearly every patient was infected with a distinct or unique Candida 
strain. 
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Investigation of Candida albicans transmission in a surgical 
intensive care unit cluster by using genomic DNA typing 
methods 
Andreas Voss. Michael A. Pfaller, Richard J Hollis, Janet Rhine-Chalberg, and Bradley N. 
Doebbeling. 
Journal of Clinical Microbiology 1995,33:576-580 
Abstract 
An apparent outbreak of serious Candida albicans infections (n=6) occurred in a surgical §• 
intensive care unit over a 4-week period. Four patients developed С albicans bloodstream „ 
infections. An additional patient developed catheter-related С albicans infection; the sixth ^ 
Φ 
patient developed an infection of cerebrospinal fluid. C. albicans was isolated from the hands 3 
η 
of five health care workers (17%) and the throat of one health care worker (3%) during the Q 
outbreak investigation. Karyotyping and restriction endonuclease analysis of genomic DNA g 
о 
with ßssHIl of 23 С. albicans isolates from patients and the 6 health care worker isolates 5 
S" 
revealed 9 and 12 different patterns, respectively. Three of six patients appeared to be Û 
infected with the same С albicans strain (two bloodstream infections and one cerebrospinal 
fluid infection). The hands of a health care worker were colonized with a strain that appeared 
identical to an isolate from a patient prior to infection of the patient. However, restriction 
endonuclease analysis with Sfil found differences among the isolates determined to be 
identical by the other two methods. Karyotyping alone does not appear to be sufficient to 
differentiate between outbreak and control isolates. Restriction endonuclease analysis typing 
may be a more sensitive method than karyotyping alone in the Investigation of a cluster of C. 
albicans infections. Furthermore, the use of more than one restriction enzyme may be 
necessary for optimal strain discrimination in restriction endonuclease analysis of genomic 
DNA. 
Introduction 
In recent years, the Candida species have emerged as important nosocomial pathogens. 
Over the past decade, the incidence of Candida bloodstream infections increased by 219 to 
487% in U S. teaching hospitals and by 75 to 370% in non-teaching hospitals8 1 8 3. Candidemia 
occurs most frequently in immunocompromised patients with an underlying malignancy or 
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hematologic disorder , 1 5 1 1 7 and in severely ill burn patients as well as surgical intensive care 
unit (SICU) and neonatal intensive care unit (ICU) patients 272933155197216 Therefore incidence 
rates of candidemia are highest in tertiary care referral hospitals The incidence rate at the 
University of Iowa Hospitals and Clinics is 8 5 per 10 000 admissions with 57% crude and 38% 
attributable mortalities2 3 7 
Until recently the development of invasive Candida infections was thought to be more or less 
exclusively due to autoinfection by endogenous Candida strains which initially colonize the 
patient Using molecular typing methods investigators have confirmed this hypothesis in 
neutropenic and nonneutropenic patients ue 214 222 However exogenous sources responsible 
for outbreaks have been described increasingly including cross-infection among ICU patients 
74 attributed to hand carriage by health care workers (HCWs) 2 7 7 1 contaminated medications 
pressure transducers parenteral nutrition and reused disposable devices 123 192 201233 235 239 | n 
m 
j [ half of such outbreaks reviewed by Sherertz et al " 2 the source could not be identified 
(P 
3 possibly because of the lack of reliable and readily available typing methods for Candida 
о 
S species 
~< 
2, We report an outbreak of systemic Candida albicans infections in a SICU in which apparently 
~ identical isolates were recovered from three patients sites of infection and from the hands of 
ñ an HCW prior to development of infection in one of the patients The epidemiology of the 
0 carnage and transmission of С albicans among patients in the SICU was further clarified by 
о. the application of molecular typing methods 
о 
5 
О 
1 Materials and Methods 
Hospital and patients The University of Iowa Hospitals and Clinics is a 900-bed teaching 
hospital and tertiary care referral center with approximately 200 beds designated for 
intensive care The SICU (Figure 1 ) at the time of the cluster of infections was divided into four 
bays with a total of 24 beds The nurse to patient ratio ranged from 1 2 to 1 1 depending on 
the patients needs and availability of nursing staff A mean of 164 patients per month 
(standard deviation ± 12) were admitted to the SICU during the 9 months prior to the 
outbreak During the 4-week period of the outbreak 163 patients had been admitted to the 
SICU The unit is prospectively surveyed by trained infection control nurses each weekday 
Additionally the surveillance system has been prospectively validated recently 21 No 
significant changes in personnel equipment or infection control surveillance or definitions 
occurred during the outbreak period or in the previous 9 months 
Outbreak description During the period of the cluster the observed rate of С albicans 
bloodstream infections exceeded the upper limit of the predicted 95% confidence interval 
and an outbreak investigation was initiated Microbiological data infection control 
surveillance data and clinical information for all patients were reviewed in search of a 
common source or vehicle In order to determine current rates of carriage among SICU 
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workers, the hands and throats of 30 HCWs were sampled prospectively at random intervals 
over the next 2 weeks by using the broth-bag technique , 5 7 and sterile premoistened rayon-
tipped swabs (Culturette II Marion Scientific Kansas City, Mo ), respectively Pressure 
transducers of patients receiving intra-artenal monitoring and the ward stock insulin in use 
were also cultured Similarly the throats and stools of patients in the SICU over the 5 weeks 
following the identification of the outbreak were also cultured at random intervals All 
Candida isolates were banked and identified to the species level by using the API 20C system 
(Analytab Products, Plamview, Ν Y ) Cases were identified by reviewing microbiology reports 
and patient data from charts and the hospitals mainframe computer and data gathered by 
infection control nurses The importance of hand washing and compliance with the 
guidelines for prevention of nosocomial infections were reemphasized at the time of the 75 
identification of the cluster 
m 
Molecular typing Molecular typing of all isolates was accomplished by electrophoretic Q. 
karyotype (EK) analysis and by restriction endonuclease analysis of genomic DNA (REAG) § 
using the restriction enzymes BssHII (REAG-B) and Sf/I (REAG-S) followed by pulsed-field gel <§ 
о 
electrophoresis Electrophoretic karyotyping and REAG were performed as described ЗГ 
previously 3 ' 4 1 2 2 2 о 
Analysis EK and REAG profiles were analyzed by visual inspection of photographs of " 
ethidium bromide-stained gels Photographs were analyzed to detect similarities and ^ 
differences in banding patterns by three observers who were blinded to the origin of the о 
isolate and the results of the other observers Isolates were considered identical when all of g 
the bands matched similar when > 95% but < 100% of the bands matched, and different | 
when < 95% of the bands matched Interobserver reliability was calculated by using the 
kappa coeff icient 2 4 7 
Results 
Patients Between 14 October and 22 November 1990, a total of six serious С albicans 
infections occurred in an open SICU ward with adjacent beds in which patients were close 
together and often cared for by the same HCW (Figure 1) Four of the six patients had 
candidemia one had a catheter-related infection and one had a central nervous system 
infection The incidence density ratio for candidemia during the outbreak period was 
significantly elevated 4 infections per 577 patient days versus 4 per 6,430 patient days in the 
entire year (incidence density ratio 11 1 (95% confidence interval 2 79 to 44 56) Similarly the 
incidence density rate difference was 0 0063 (95% confidence interval 0 0005 to 0 01) the 
underlying diseases and risk factors for infection of the six patients involved in the cluster are 
shown in Table 1 Four patients had undergone abdominal surgery and five had diabetes 
mellitus as their major underlying disease Risk factors for infection included intravascular 
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catheters for six patients, five or more antibiotics for five patients, and total parenteral 
nutrition for four patients (Table 1). 
Table 1 . Underlying diseases and risk factors of SICU cluster patients 
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CD 3 
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о 
CÛ 
φ 
3 
о' 
О Q 
D 
a 
a 
Q 
Risk factor 
Infection0 
CRI 
CSF 
BS I 
IV catheter 
Central venous 
Arterial line 
Peripheral line 
No. of antibiotics 
< 4 
>5 
TPNb 
Abdominal surgery 
Diabetes mellitus 
S 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
w 
+ 
+ 
+ 
+ 
+ 
+ 
Presence of factor for patienf: 
К 
+ 
+ 
+ 
+ 
+ 
+ 
с 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
A 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
D 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
a
 CRI: catheter-related infection; CSF: cerebrospinal fluid; BSI: bloodstream infection 
b
 TPN: total parenteral nutrition 
φ 10/28-11/19' 
φ 11/8-12/20 
! — ι 
s 
A 
С 
W 
К 
D 
10/1 - 10/19 
10/27-11/14· 
10/25- 11/24* 
10/28-11/19· 
10/25-11/19· 
11/8-12/20 
10/14 
10/30 
11/6 
11/7 
11/9 
11/22 
О • Bay in which Candida 
infection developed 
* = Patient died 
FIG. 1. Schematic diagram of bays I to 4 of the SICU, showing the initial localization and transfer of the cluster patients. 
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Microbiological surveillance. Following identification of the cluster, the hands and throats 
of 30 different HCWs were cultured. Seventeen percent of the hand cultures and 33% of the 
throat cultures of HCWs yielded C. albicans. At the same time the throats of 33% of the 
patients and the stools of 15% of the patients were colonized with C. albicans. In the 
subsequent 3 weeks, rates of C. albicans colonization among patients were 30 and 12% for 
the throat and stool, respectively. This difference was not statistically significant (P>0.20). 
Molecular typing. In the analysis of the DNA profiles of the isolates a high degree of 
interobserver reliability was observed: the generalized kappa statistics were 0.84 or greater for 
EK and REAG-B and REAG-S profiles (P<0.001 for each). The results of the overall interpretation 
(consensus call of the three observers) are given in Table 2. 77 
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Table 2. Summary results of karyotyping and REAG 
Patient 
orHCW 
S 
A 
W 
D 
HCW 1 
С 
К 
Patient 1 
Patient 2 
HCW 2 
HCW3 
HCW 4 
HCW 5 
Isolate 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
Origin 
Catheter 
Catheter 
Blood 
Blood 
Urine 
Urine 
Urine 
Blood 
CSFb 
Trachea 
CSF 
Blood 
Eye 
Hand 
Throat 
Catheter 
Blood 
Catheter 
Trachea 
Trachea 
Blood 
Trachea 
Sputum 
Trachea 
Hand 
Hand 
Hand 
Hand 
Karyotype 
A 
A 
A 
A 
A 
A 
A 
A 
В 
В 
В 
A 
С 
A 
A 
D 
D 
D 
D 
A 
E 
A 
E 
F 
С 
G 
H 
1 
REAG-B 
type a 
la 
la 
l b 
l a 
le 
le 
le 
le 
2 
2 
2 
3 
4 
l e 
le 
5 
5 
5 
5 
3 
5 
3 
6 
7 
8 
9 
10 
l e 
REAG-S 
type a 
1 
1 
II 
II 
II 
II 
II 
II 
Illa 
Illa 
Illa 
Illa 
IV 
V 
VI 
lllb 
lllb 
lllb 
lllb 
IV 
V 
IV 
VI 
VII 
IV 
Vili 
IX 
X 
a
 Lowercase letters indicate subtypes with >95% but <100% matching bands 
b
 CSF: cerebrospinal fluid 
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FIG. 2. Representative EK profiles of С albicans. Lanes: S, Saccharomyces 
cerevisiae chromosome DNA size standards (sizes are indicated on the right); 1. 
С afticom control strain; 2 and 3, EK E; 4, EK H; 5, EK F; 6, EK G; 7, EK D; 
8 to 10, EK A. 
Panent S A W D HCWI 
Isolate 1 2 L 3 4 5 6 7 8 . 9 1 0 l 1 , t 1 2 13¡14 15 
727 kb 
485 kb 
242 kb 
48.5 kb 
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FIG. 3. Types of С albicans obtained by REAG-B followed by pulsed-field 
gel electrophoresis. Results are shown for blood culture and other-site isolates 
trom patients S, A, W, and D and HCW 1. Lane numbers correspond to the 
isolate numbers in Table 2. Banding patterns of isolates from patients S and A 
and HCW 1 represent identical or closely related subtypes (5:95% of bands .in. 
shared). Lanes L, molecular size standards (lambda phage DNA concalemers 
sizes are indicated on the rieht). 
Patient S A W D HCWI 
Isolate 1 2 L 3 4 5 6 7 8 9 10 11 L 12 13 14 15 
242 kb 
48 5kb 
FIG. 4. Types of C. albicans obtained by REAG-S followed by pulsed-field 
gel electrophoresis. Isolates are the same as for Fig. 3. Differences in banding 
patterns are seen among isolates from patients S and A and HCW 1, as well as 
patients W and D. Lanes Ц molecular size standards (lambda phage DNA 
eoncalemers; sizes are indicated on the right). 
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A total of 20 isolates from six outbreak patients (patients S, A, W, D, C, and K), the hand 
isolates from the five HCWs with positive cultures, and isolates from two additional SICU 
patients (patients 1 and 2) colonized with С albicans following the outbreak were typed by 
all three methods EK analysis and REAG-B and REAG-S identified 9, 10 and 10 different 
patterns, respectively (Table 2 and Figure 2 to 4) The combination of all three methods 
(composite DNA type) identified 16 different profiles 
Identical EK patterns (EK A) were obtained for all isolates from patients S and A and from the 
hands and throat of HCW 1 Additionally, EK A was found in the blood and trachea of 
patients D and K, respectively (Table 2) In contrast, distinctly different EKs were observed for 
isolates from patients W and C, SICU patients 1 and 2, and HCWs 2 to 5 (Table 2) For six of the 
seven individuals with two or more isolates of С albicans, the same EK was observed on more 79 
than one occasion and/or for specimens from more than one anatomic site 
ГП 
The relationship among isolates determined by REAG-B generally supported that determined 0. 
a> 
by EK analysis (Table 2) All isolates from patients S and A and HCW 1 had the same basic § 
0 
REAG-B profile (type 1 ), allowing for minor banding differences (shared > 95% of bands. Figure <§ 
о 
3) REAG-B also found the blood and tracheal isolates from patients D and К to be identical ~ 
(type 3) but different from the isolates of patients S, A and HCW 1 despite a common EK » 
(Figure 3) As with EK analysis, the isolates from patients W and C, SICU patients 1 and 2 and " 
Q 
HCWs 2 to 5 were all different as determined by REAG-B Likewise, REAG-B demonstrated that ^ 
a 
multiple isolates from the same patient generally had the same DNA banding pattern (Figure a 
3) I 
In contrast to the findings with EK analysis and REAG-B, REAG-S identified differences among § 
the outbreak isolates (Table 2 and Figure 4) Specifically isolates from patients S and A and 
HCW 1 each had a different REAG-S profile despite having the same EK and REAG-B types 
(Table 2 and Figure 3 and 4) Several patients had the same REAG-S profile REAG-S type III 
was shared by patients W, D, and C, type IV was shared by patients D and К and HCW 2, 
type V was shared by HCW 1 and patient К and type VI was shared by HCW1 and patient 1 
(Table 2) However these isolates were identified as different strains on the basis of REAG-B or 
EK analysis (Table 2) As with the other typing methods, multiple isolates from the same patient 
generally had the same REAG S profile 
When the results of all three typing methods were considered (composite DNA type), a total 
of 16 DNA types were identified among 27 isolates from 13 individuals (Table 2) None of the 
composite DNA types were shared by two or more individuals Patients S, A, W and С each 
maintained their own unique DNA type of С albicans over time and from multiple anatomic 
sites whereas patients D and К and HCW 1 each had two different DNA types colonizing or 
infecting different anatomic sites 
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Discussion 
One of the important considerations regarding the prevention and control of nosocomial 
candidiasis is whether the infection is endogenous or exogenous to the patient M 0. It is 
reasonable to assume that endogenous forms of infection may require strategies for 
prevention (e.g., antifungal prophylaxis) which are different from those for exogenous 
infections due to transmission of any organism from patient to patient (hand washing and 
other infection control measures). Our understanding of this area is still evolving; however, the 
use of molecular typing methods to fingerprint Candida species has been very useful in 
epidemiologic studies designed to address these issues3 9 , 5 B , 9 2 2 0 1 2 2 2 . 
80 The evidence for endogenous candidal infection in hospitalized patients includes the findings 
that unique strains of Candida are usually seen for each patient, that the same Candida DNA 
Ρ 
a type is usually isolated from multiple anatomic sites over time, that colonizing and infecting 
Φ 
§ strains are usually the same DNA type, and that the colonizing isolate usually precedes the 
S infecting isolate '5 8 2 2 2. 
^ Despite the importance of endogenous infection, there are now several reports documenting 
• < 
j transmission of Candida species from patient to patient, particularly in the ICU setting 
3 
η 274471197214 The open nature of many ICUs and the level of activity make it difficult to 
о § implement or enforce infection control practices, thus facilitating nosocomial transmission of 
a 
g- pathogenic organisms such as Candida species. Evidence for carriage of the infecting strain 
3, of Candida on the hands of HCWs is mounting, suggesting that simple hand washing may be 
g an effective infection control measure 394°. Unfortunately, compliance with hand-washing 
policies among HCW personnel is less than optimal and underscores the problem of 
controlling nosocomial transmission of Candida and other pathogens M . 
In the present study, we investigated a cluster of Candida infections in a single ICU in which 
surveillance cultures indicated hand carriage by several HCWs of the same species of 
Candida (C. albicans) earned by the infected patients. The clustering of these infections in 
time and space coupled with hand carriage of the infecting species suggested the possibility 
of nosocomial transmission. The epidemiology was clarified by the use of DNA-based typing 
methods, including EK analysis and REAG-B and REAG-S. 
Application of EK analysis alone suggested infection of four patients and colonization of one 
HCW with a single strain of C. albicans Two additional patients shared a second EK of 
C. albicans, and the remaining patients and HCWs were each colonized with their own 
unique EK. This relationship among isolates and patients was corroborated by REAG-B. 
Importantly, apparently the same strain eventually causing infection in a previously 
uninfected patient was identified on the hands of an HCW prior to development of infection 
in that patient. Isolates from two patients and one HCW had the same EK and REAG-B type, 
suggesting limited nosocomial transmission of a single strain of С albicans and linking the 
HCW to the two infected patients 
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One of the major tenets of epidemiologic typing is that although one or more typing methods 
may be used to demonstrate convincingly that two nosocomial pathogens are different from 
one another, it is very difficult to prove that they are the same strain. To this end, 
epidemiologic typing systems are used in combination to enhance discrimination among 
bacterial isolates. However, this combined approach has been used infrequently for Candida 
species. Previously, Hunter and Fraser70 have demonstrated enhanced discriminatory power 
for typing isolates of C. albicans with the combination of resistotyping and morphotyping, 
suggesting that two or more methods employed in parallel or in a hierarchical fashion may 
be necessary for epidemiologic studies of C. albicans. More recently, Mercure et al. l n 
demonstrated enhanced discrimination among C. albicans strains, using two DNA-based 
typing methods, restriction fragment length polymorphism analysis and Southern hybridization 81 
with DNA probe 27A. In the present study, further analysis of the C. albicans isolates with a 
m 
second restriction enzyme, Sf/I, identified differences among the isolates with identical EK and a. 
REAG-B profiles, indicating that they may not be clonally related. The combination of ΕΚ § 
о 
analysis and REAG with two enzymes revealed unique DNA profiles for isolates from each <° 
о 
patient and HCW. No two isolates from patients or HCWs shared all of the DNA markers. ;r 
Despite the great heterogeneity among DNA types generated by the composite (EK, REAG-B, jj 
and REAG-S) typing approach, the ability of this approach to identify related strains within an " 
о 
individual patient remained intact. Although we observed three individuals infected or ^ 
a 
colonized by two strains of С albicans, the overall pattern was similar to that described о 
previously l 5 8 2 2 2 in that patients with multiple isolates were generally colonized and infected j» 
by a single strain of C. albicans that persisted over time and multiple anatomic sites. Overall, § 
five of the six patients in this study were found to be infected or colonized by their own unique 
strain on two or more occasions. 
In summary, distinct DNA types of clinical isolates of C. albicans were identified by using a 
composite approach of electrophoretic karyotyping and REAG with two different restriction 
enzymes. The combination improved strain discrimination compared with that of any one of 
the typing methods used alone. Epidemiologic investigation demonstrated that an individual 
patient usually harbored a single composite DNA type of C. albicans that was not shared with 
those of other patients or HCWs. These findings speak against nosocomial transmission of a 
single strain as a cause of the entire cluster of C. alb/cans infections. The fact that isolates 
from patients S and A and HCW 1 had the same strain of С albicans as determined by two of 
the three molecular typing approaches (EK analysis and REAG-B) suggests that some 
transmission may have occurred on a small scale. Differences observed with the third typing 
approach (REAG-S) may reflect the propensity for C. albicans to undergo genomic 
rearrangements and suggests that although these isolates may have had a common origin, 
direct patient-to-patient or HCW-to-patient transmission is unlikely. Molecular typing methods 
may be used effectively to clarify the epidemiology of nosocomial infections; however, the 
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various typing methods must be used with the understanding that more than one approach 
may be necessary to achieve optimal strain discrimination. 
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Chapter 4 
Chapter 4.1 
Occurence of yeast bloodstream infections between 
1987 and 1995 in five Dutch university hospitals 
Andreas Voss, Jan AJ.W Kluytmans, Johannes G M. Koeleman, Lodewijk Spanjaard, 
Christina M.J E Vandenbroucke-Grauls, Henri A. Verbrugh, Margreet C. Vos, Annemarie 
Y L Weersink, Jacomina A.A Hoogkamp-Korstanje, and Jacques F G.M. Meis 
European Journal of Clinical Microbiology and Infectious Diseases, 1996; 15:909-912 
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Abstract 
m 
"D 
a 
a> 
The aim of this study was to identify retrospectively trends in fungal bloodstream infections in § 
Ö" 
The Netherlands In the period from 1987 to 1995. Results of over 395,000 blood cultures from ξ 
о 
five Dutch university hospitals were evaluated. Overall, there were more than 12 million ~ 
-< 
patient days of care during the nine-year study period. The rate of candidemia doubled in У 
the study period, reaching an incidence of 0.71 episodes per 10,000 patient days in 1995. The " 
general increase in candidemia was paralleled by an increase in non-Candida albicans => 
bloodstream infections, mainly due to Candida glabrata. However, more than 60% of the о 
infections were caused by Candida albicans. Fluconazole-resistant species, such as ® 
Candida krusei did not emerge during the study period. i 
The increasing rate of candidemia found in Dutch university hospitals is similar to the trend 
observed in the USA, but the rate is lower and the increase is less pronounced. 
Introduction 
In recent years, Candida species, most notably Candida albicans, have emerged as 
important nosocomial pathogens Over the past decade, the incidence of Candida 
bloodstream infections mcreused by two- to fivefold in teaching hospitals and by one- to 
fourfold in non-teaching hospitals in the USA віэівэ Candidemia occurs most frequently in 
high-risk patients, iuch as immunocompromised patients with an underlying malignancy or 
hematological disorder , 1 5 1 1 7 , severely ill burn-patients, and surgical and neonatal intensive 
care patients 2729117155197216 Therefore, the incidence of candidemia is highest in tertiary 
care referral hospitals, with an incidence of 5-10 per 10,000 admissions 8 Nosocomial 
candidemia now accounts for 10%-15% of all hospital-acquired bloodstream infections in 
hospitals in the USA, Candida thus being among the four predominant microorganisms 
causing nosocomial bloodstream infections 8 ' " Clearly, candidemia is posing an ¡ncreasing-
Clmical epidemiology of Candida bloodstream infechons 
ly serious problem ¡η infectious diseases, and has been shown to be associated with 57% 
crude and 38% attributable mortality rates2 3 7. 
As neither the prevalence nor incidence of nosocomial fungal bloodstream infections in The 
Netherlands is known, the aim of this study was to identify trends in yeast bloodstream 
infections retrospectively in this country, by evaluating computerized laboratory and census 
data from five of the eight Dutch university hospitals. 
Patients and Methods 
Five university hospitals in The Netherlands participated in the study, including two hospitals in 
86 Amsterdam and one each in Rotterdam, Utrecht, and Nijmegen. The overall bed capacity of 
these five hospitals, which serve as tertiary-care referral centers for roughly two-thirds of the 
a population of The Netherlands, is approximately 5,500. 
CD 
§· Episodes of fungemia were identified retrospectively from microbiology data systems using 
<o computer-generated lists of patients whose blood cultures yielded yeasts during the period 
~ from 1 January 1987 to 31 December 1995. All patients admitted to the study hospitals were 
• < 
y eligible for enrollment An episode of fungal bloodstream infection was defined as at least 
r>' one positive blood culture yielding yeast during a single hospitalization period. The number of 
Γ) § blood culture sets examined per year and their outcomes (negative, positive bacterial, 
a 
g· positive fungal) were reported. All microbiological data were taken at face value, 
2. disregarding the different blood culture- and identification-systems used in the participating 
g hospitals. Between 1991 and 1992 automated blood culture systems were implemented in all 
participating hospitals. None of the hospitals used the lysis centrifugation system. Census 
data to determine patient days were retrieved from the hospital's information systems. 
Results 
During the nine-year study period from 1987 to 1995, the five university hospitals delivered a 
total of 12,353,861 patient days of care, averaging 1,372,600 ± 32,300 (mean ± SD) patient 
days per year. The number of patient days decreased over the years from 1,426,319 in 1987 
to 1,322,338 in 1995. In contrast, the number of admissions (118,966 in 1987; 128,864 in 1995), 
and the number of blood cultures taken per year (34,450 in 1987; 49,203 in 1995), increased 
by 8.3% and 42.8%, respectively. 
The proportion of positive blood cultures (with no regard for clinical significance) was 19% ± 
2.9% (mean ± SD), remaining stable over the years. The proportion of positive blood cultures 
yielding yeasts ranged from 3.2% in 1988 to 5.6% in 1993. 
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Overall, 671 episodes of yeast bloodstream infections occurred during the study period 
(Table 1); 635 episodes (94.6% + 2.9%) were due to Candida species, and 46 episodes (6.8%) 
were due to Cryptococcus species. 
Table 1: Overall episodes of yeast bloodstream infections in the study period. 
Yeast (n=671) 
Overall no 
No. per 10,000 PD 
Candida (n=625) 
Overall no 
No. per 10.000 PD 
Cryptococcus (n=46) 
Overall no 
No. per 10.000 PD 
1987 
57 
.40 
53 
.37 
4 
.03 
1988 
48 
.34 
45 
.32 
3 
.02 
1989 
70 
.51 
63 
.46 
7 
.05 
1990 
64 
.46 
59 
.43 
5 
.03 
1991 
73 
.54 
67 
.50 
6 
.04 
1992 
70 
.50 
67 
.48 
3 
.02 
1993 
111 
.82 
101 
.74 
10 
.07 
1994 
78 
58 
75 
.56 
3 
.02 
1995 
100 
76 
95 
.72 
5 
04 
Mean/SD 
7 4 . 6 / 19.9 
. 5 5 / . 1 6 
6 9 . 4 / 18.4 
.31 / . 1 5 
5.1 / 2 . 3 
. 0 3 5 / . 0 1 7 
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The rates of yeast bloodstream infections in The Netherlands during the study period are 
given as episodes per 10,000 patient days (Table 1). The lowest rate was seen In 1988 (0.34 
episodes per 10,000 patient days); the highest rate in 1993 (0.82 episodes per 10,000 patient 
days). Figure 1 depicts the Individual rates for C. albicans and non-C. albicans. During the 
study period, the rate of bacteremia Increased from 15.2 episodes per 10,000 patient days to 
23.5 episodes per 10,000 patient days in 1987 and 1995, respectively. Therefore, all rates 
showed the same, increasing trend. Importantly, there was no significant difference between 
the rate of candldemia due to С albicans and non-C. albicans species. During the study 
period, fluconazole was licensed for sale in The Netherlands. The annual use of fluconazole, 
estimated from the nation-wide sale figures (data supplied by Pfizer, The Netherlands), 
Increased by factor four from 15.5 kg in 1990 to 63.0 kg in 1995 (Figure 1). 
The number of episodes of fungemla caused by the different Candida species and the 
proportion due to the individual non-C. albicans species is shown in Table 2. The increase of 
non-C. albicans species was mainly due to Candida glabrata. Interestingly, the number of 
episodes of candidemia due to Candida krusei was very low throughout the study period 
(Figure 2). 
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Figure 1: Episodes of C. albicans and non-C. albicans fungemia per 10,000 patient days 
(PD) in five Dutch university hospitals, and the yearly use of fluconazole estimated 
from the nationwide sale of capsules (50, 150, 200 mg) and vials( 100 and 200 mg). 
Table 2: Episodes of fungemia (nj caused by individual Candida species and proportion of 
candidemia due to non-cand/da-albicans species (NCAS) 
G albicans 
Non-C. albicans 
C. glabrata 
С tropicalis 
С. krusei 
С. parapsilosis 
С. guillermondii 
Other species 
Not determined* 
Subtotal (NCAS) 
% 
Total 
1987 
39 
3 
2 
2 
4 
0 
0 
3 
14 
26.4 
53 
1988 
32 
3 
1 
1 
1 
1 
0 
6 
13 
28.9 
45 
1989 
45 
5 
2 
0 
1 
0 
1 
9 
18 
28.6 
63 
1990 
43 
3 
1 
0 
4 
0 
1 
7 
16 
27.1 
59 
1991 
42 
5 
3 
1 
2 
1 
5 
9 
26 
38.2 
68 
1992 
46 
2 
1 
0 
4 
1 
4 
9 
21 
31.3 
67 
1993 
61 
14 
3 
0 
6 
3 
3 
11 
40 
39.6 
101 
1994 
46 
10 
4 
2 
2 
1 
3 
7 
29 
38.7 
75 
1995 
57 
16 
4 
2 
2 
2 
3 
9 
38 
40.0 
95 
NCAS = non-C. albicans species 
* mostly originating from one study center that only differentiated C. albicans and NCAS 
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In the last year of the study period, 40% of all Candida bloodstream infections were due to 
non-C. albicans species, with C. glabrata accounting for 42% or 55% of those episodes 
(depending on whether the figures for the non-determined species were included or not, see 
Table 2). 
Episodes 
70 
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20 
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1987 1988198919901991 199219931994 1995 
• C. albicans 
 •III III Ml 
ilil II 
1987 1988 1989 1990 1991 1992 1993 1994 1995 
Figure 2: Occurrence of C. albicans, C. glabrata, and С krusei, among blood culture 
isolates in five Dutch university hospitals from 1987 to 1995. 
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Major changes have occurred in hospital populations, health care technology, and the use 
of antimicrobial drugs during the last two decades. Data from the National Nosocomial 
Infections Surveillance System and other hospitals in the USA show that these changes have 
had a profound impact on the epidemiology of fungal infections, including the increasing 
incidence of Candida bloodstream infections 8.Ш8ШІ, $ 0 f a r / o n | v o n e European study has 
addressed the increasing problem of fungemia. Bruun et al. 24 showed an increase in the 
annual incidence of fungemia at a Danish university hospital from 19 episodes in 1989 to 57 
episodes in 1994. Unfortunately, the authors gave no rates, thereby making it impossible to 
compare their findings with the literature and introducing the possibility of bias due to a likely 
increase in the number of blood cultures taken, as demonstrated in our study. 
Pittet and Wenzel 150 reported a linear increase in the rates of nosocomial bloodstream 
infections at the University of Iowa Hospitals and Clinics (UIHC) between 1981 (67 episodes 
per 10,000 patient days) and 1992 (184 episodes per 10,000 patient days). Statistically 
significantly increased rates were demonstrated for the four predominant blood culture 
isolates, coagulase-negative staphylococci, Staphylococcus aureus, enterococci, and 
Clinical epidemiology of Candida bloodstream infections 
Candida species Rates of candidemia increased 12-fold during the study period described, 
reaching a peak of two episodes per 10,000 patient days in 1991 l5° The rates of bacteremia 
and candidemia found in Dutch university hospitals show the same, increasing trend, but on 
a lower scale In 1991, we found 0 5 episodes of candidemia per 10,000 patient days, a rate, 
fourfold lower than the UIHC rate Even three years after the end of the study in the USA, the 
rate of candidemia in Dutch university hospitals is still 2 8-fold lower (0 72 episodes per 10,000 
patient days) In general, the rates of candidemia in The Netherlands are not only lower but 
the increase is less dramatic (2 3-fold compared to 12-fold, at the UIHC) This difference 
between the USA and The Netherlands might be due to the very restricted antibiotic policy 
of Dutch physicians both within and outside the hospital, which is reflected in the low 
90 incidence of other multi-resistant pathogens, such as penicillin-resistant pneumococci, 
methicillm-resistant Staphylococcus aureus, and vancomyan-resistant enterococci а ι ο β ' , 3 " ' 
m 
Ό 
Q. 
CD 
3 Overall, 60% of all candidemic episodes in the study period were caused by С albicans, but 
о 
(Û the proportion of candidemic episodes due to non-C albicans species increased from 26% 
-< 
2, to 40% This increase was due mainly to a rising number of episodes due to С glabrata, a 
• < 
¡s. Candida species with reduced susceptibility to fluconazole During the study period, the 
ñ rates of candidemia due to Candida species with reduced fluconazole susceptibility 
о (C glabrata and С (cruse/) increased 4 7-fold (0 03 per 10,000 patient days in 1987 versus 0 14 
о. per 10,000 patient days in 1995) compared to an 2 8-fold increase (0 06 per 10,000 patient 
о 
5 days in 1987 versus 0 17 per 10,000 patient days in 1995) for the other non-C albicans species 
ЙГ 8- However, other factors besides the increased use of fluconazole in The Netherlands may 
о 
have contributed to this species shift and should be identified in future investigations 
Changes in blood culture technique, most importantly the introduction of agitation (1991/92), 
may have influenced our general findings, but were not the only factors influencing the 
general trend, since this would have resulted in a sudden increase with only minor changes in 
the period before and after the introduction 
To what degree demographic changes in patient population may have contributed to the 
observed trend is not clear During the study period the number of admissions and thus the 
number of patients who could develop candidemia increased, but at the same time, the 
average time of hospitalization decreased (from 12 1 days in 1987 to 10 3 days in 1995) 
thereby reducing the chance of the individual patient acquiring systemic candidosis 
The introduction of new diagnostic and therapeutic techniques, and the increased and 
prolonged use of multiple antimicrobial agents in a growing proportion of severely ill patients 
(reflected in the growing number of blood cultures taken) may be other factors contributing 
to the increase of nosocomial Candida bloodstream infections in Dutch university hospitals 
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Chapter 4.2 
Candidemia in intensive care unit patients: risk factors 
for mortality 
Andreas Voss, Jos L M L le Noble Frans M Verduyn Lunel, N o r b e r t Foudraine, and Jacques 
FGM Meis 
Infection, 1997,25 8-11 
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Aim of this study was to evaluate whether risk factors which predict the d e v e l o p m e n t of § 
5" 
c a n d i d e m i a m a y furthermore predict d e a t h In ICU patients with c a n d i d e m i a . During a B-year- <§ 
о 
period all ICU patients whose blood cultures yielded Candida species (n=40) w e r e ^ 
retrospectively e v a l u a t e d in a case-control fashion. The a v e r a g e i n c i d e n c e of Candida j» 
bloodstream infections was 5.5 per 10,000 patient days, ranging from 2.4 in 1990 to 7.4 in 1994. " 
Q 
C. albicans was the most c o m m o n p a t h o g e n in c a n d i d e m i c patients, but the proportion of ^ 
non-C. albicans strains showed an increasing trend during 1989-1993, with a major shift о 
towards non-C. albicans species in 1994. The overall mortality of patients with c a n d i d e m i a g 
was 5 8 % . Mortality was highest in the group of patients with multi-organ dysfunction § 
syndrome, especially a m o n g those in n e e d of hemodialysis. Risk factors for the d e v e l o p m e n t 
of c a n d i d e m i a , such as a g e , malignancy, steroid use, iv catheterization, a n d the use of b r o a d 
spectrum antibiotics w e r e not correlated with mortality in our ICU patients. 
Introduction 
ICU patients account tor only a small part of the hospital population, but contribute 
considerably (about one fouith) to the overall rate of endemic and epidemic nosocomial 
infections l 0 7 2 1 2 Development of hospital-acquired infections is a major determinant of 
morbidity and moitahty in these patients 
Candidemia occurs most frequently in immunocompromised patients with an underlying 
malignancy or hematological disorder as well as surgical and neonatal intensive care unit 
patients 272938216 in recent years the incidence of Candida bloodstream infections increased 
dramatically with Candida advancing to be the third to fourth most common pathogen 
causing bloodstream infections 821147195 |n general, critically ill patients who develop 
nosocomial bloodstream infection are at greater risk to die, than patients with comparable 
severity of underlying disease without this complication " 5 Patients with fungal bloodstream 
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infection, such as those due to Candida, where shown to have the shortest survival prospects 
of any blood-borne infection 1β1. Wey et a l . 2 3 β reported in a well matched case-control study 
a crude a n d attributable mortality of 57% and 38%, respectively. 
Various risk factors for the development of systemic Candida infections have been reported, 
among which the severity of underlying illness (assessed by APACHE II), number and extend of 
prior antibiotic therapy, concomitant isolation of Candida species from other sites, the presence 
of central venous catheters, and prior hemodialysis were proven in multiple logistic regression 
models, or were unanimously identified by all investigators23 ы 9 23β. 
The purpose of this paper was to evaluate whether risk factors for the development of 
candidemia may be used to identify ICU patients at risk to die from Candida bloodstream 
92 infections. Improved stratification of the risk of candidemia would help to identify ICU patients 
in whom pre-emptive treatment with toxic and/or expensive (new) antifungal agents would be 
m 
5; reasonable. Furthermore, we examined whether an increased incidence of candidemia and 
(D 
3 mortality is attributed to the emergence of non-C. albicans species. 
о 
о 
<o 
S. Patients and Methods 
• < 
φ 
3 
о The University Hospital Nijmegen is a 980-bed tertiary care teaching hospital with several 
О § intensive care facilities. The central ICU encompasses 37 beds, primarily directed at patients 
g 
g- recovering from thoracic and abdominal surgery. Results of all blood cultures from patients 
3, admitted to the ICU between 1-1-1987 and 31-12-1994 were screened for Candida species. 
Φ 
g· All patients with at least one blood culture positive for a Candida species were objected to a 
retrospective chart review and analyzed in a case-control fashion. Candidemic patients who 
died during their ICU stay (non-survivors) were considered as cases; those surviving candidemia 
and being discharged from the ICU served as controls (survivors). 
Census data of the department of intensive care were used to calculate incidence of 
candidemia, which was expressed as cases per 10,000 patient days. Furthermore, the distributi­
on between incidence of Candida albicans versus non-C. albicans strains was determined. 
Medical records of all selected cases were reviewed for patient demographics, seventy of 
underlying diseases (SAPS II score"), the time on ventilator, the time with indwelling intravascular 
catheters, colonization with Candida species, the length of stay in the ICU before development 
of candidemia and antimicrobial/-fungal therapy. Multi-organ dysfunction syndrome (MODS) 
was classified according to the following criteria: respiratory failure, acute respiratory distress 
syndrome (ARDS), hypotension, renal failure requiring acute hemodialysis, and hepatic dysfunc­
tion with coagulation system disorders or gastrointestinal dysfunction. 
To analyze risk factors for mortality in cases of candidemia, difference between the groups were 
evaluated by crosstabs and multiple regression analysis (SPSS for MS windows, version 6.1). The 
dependent variable was survival, independent variables were risk-factors for candidemia. 
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Results 
A total of 40 patients with positive blood cultures for Candida and available medical records 
were identified. Demographic features of the patients are depicted in Table 1. 
Table 1 : Patient demographics. 
Male/female ratio 
Age 
ICU duration 
Days in ICU until first isolation of 
Candida spp. 
Survivor (n=17) 
10/7 
54 ± 5 yr 
46 ± 9 days 
14 ± 3 days 
Non-Survivor (n=23) 
12/11 
48 ± 5 yr 
29 ± 8 days 
14 ± 4 days 
The male/female ratio was similar in survivors (n=l 7) and non-survivors (n=23). The mean age of 
non-survivors was slightly lower (48 years as compared to 54 years in survivors) but not 
significantly different. The mean length of stay before development of candidemia was 14 
days in cases and controls. 
The incidence of candidemia is shown in Figure 1. The average rate of candidemia was 5.5 per 
10,000 patient days per year, ranging from 2.4 in 1990 to 7.4 in 1994. 
cases per 
10,000 PD 
ι, 7.4 
1987 1988 1989 1990 1991 1992 1993 1994 year 
PD = patient days 
Figure 1: Incidence of Candida bloodstream infections; 1987-1994. 
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During the 8-year-period (1987-1994) C. albicans accounted for 75% of all blood culture isolates 
(Figure 2). 
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С. albicans 
75.0 % 
С. glabrata 
7.5 % 
. parapsilosis 
С. tropicalis 7.5 % 
10.0% 
Figure 2: Candida species causing bloodstream infections 1987-1994. 
Other Candida species found were Candida tropicalis (10%), Candida parapsilosis (8%) and 
Candida glabrata (8%). C. alb/cans remained the most prominent pathogen until 1994. In 1994 
the proportion of non-C. albicans species among the Candida isolates from blood cultures rose 
to 56% (Figure 3). 
1987 1988 1989 1990 1991 1992 1993 1994 
•species identification in 1987 and 1988 not reliable 
Figure 3: Proportion of non-C. albicans species causing bloodstream infections; 1987-1994. 
Antifungal treatment (mostly fluconazole, rarely amphotericin B) was started in 31 of the 40 
patients (77.5%); 82% of the survivors versus 74% of the non-survivors. Nine out of 40 patients of 
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whom six died, had no antifungal treatment. None of the patients received prophylactic 
antifungal treatment. 
Table 2 depicts the underlying diseases and co-morbidity by survival group. All patients were 
on mechanical ventilation, had Intravascular devices, and were undergoing concomitant 
broad spectrum antibiotic treatment throughout their ICU stay. All possible determinants for 
mortality were equally distributed among survivors and non-survivors, except acute 
hemodialysis, ARDS, and systemic inflammatory response syndrome with MODS. The mortality 
among patients with MODS was 91%. Within the group of non-survivors 22 patients died due to 
intractable septic shock, ARDS or MODS. One patient died due to an intracerebral hemorrhage. 
The crude mortality of all ICU patients with candidemia was 58%. 
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Table 2; Underlying diseases and co-morbidity by survival group 
Abdominal surgery 
Acute hemodialysis 
Antibacterial use 
• > 7 days 
• > 2 classes 
ARDS 
COPD 
CVC 
Diabetes mellitus 
Malignancy 
MODS 
Pneumonia 
Splenectomy 
Steroid use 
TPN 
Survivor 
(n=17) 
1 
1 
17 
12 
7 
0 
0 
15 
0 
5 
2 
2 
3 
4 
14 
Non-Survivor 
(n=23) 
11 
11 
23 
18 
11 
21 
1 
23 
1 
6 
21 
4 
2 
8 
20 
Odds ratio 
(95% CI) 
3.2(1.0-10.5) 
1.8(1.2-2.7) 
1.3(0.5-3.9) 
1.1 (0.7-2.0) 
10.8(2.9-40.9) 
1.0(0.9-1.1) 
0.9(0.7-1.0) 
1.0(0.9-1.1) 
1.0(0.6-1.4) 
10.1 (2.7-38.6) 
1.0(0.8-1.4) 
0.9(0.7-1.2) 
1.2(0.8-1.7) 
1.4(0.3-5.9) 
ARDS = acute respiratory distress syndrome, COPD = chronic obstructive pulmonory disease, CVC = central venous 
catheter, MODS = multi-organ dysfunction syndrome, TPN = total parenteral nutrition, 95% CI = 95% confidence 
interval 
In the stepwise multiple regression analysis only ARDS and MODS remained significant. The 
mean (SD) severity illness score determined by SAPS II at admission to the ICU were 47.4 (15.6) 
and 38.7 (11.0) in survivors and non-survivors, respectively. The corresponding risk of hospital 
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death in survivors and non-survivors was 55% and 30% respectively The overall SAPS II score of 
all study patients was 42 corresponding with an 38% chance of hospital death Given a crude 
mortality of 58% and a predicted mortality of 38% the attributable mortality in patients with 
candidemia was 20% 
In 51% of the study patients Candida was the first pathogen isolated from blood cultures Thirty-
three percent of the patients initially had suffered from bacteremia due to gram-negative or 
gram-positive pathogens prior to development of candidemia and in 7% of the patients 
bacteremia and candidemia occurred simultaneous In the remaining patients (9%) 
candidemia was followed by bacteremia 
96 Discussion 
a The management of patients with severe diseases and life-threatening conditions routinely 
Φ 
| involves the use of mechanical ventilation invasive monitoring parenteral nutrition and 
о 
(о indwelling catheters Obviously these patients are prone to nosocomial infections The rate 
~ of hospital-acquired infection among ICU patients is accordingly 5-10 times higher than 
• < 
у among general ward pat ients 2 I 2 
3 
η Over the past d e c a d e the incidence of Candida bloodstream infections has been reported 
о § to markedly increase in hospitals in the USA 8 2 1 l í 7 Asimilar but less striking increase has been 
g 
g- shown for most of the Dutch university hospitals223 Given the "natural" accumulation of high 
3. risk patients in tertiary care referral hospitals incidence rates of candidemia are highest in 
g these hospitals and were described to be as high as 8 5 per 10 000 admissions2M 
Mortality in most studies is high ranging from 38% to 79% The overall mortality in our patients 
with candidemia was 58% which is in accordance with previous reports In a case-control study 
performed by Wey et al 238 57 % of all patients with candidemia died whereas 38% died as a 
direct result of candidemia (attributable mortality) Our analysis showed a lower attributable 
mortality (20%) probably reflecting the severity of the already existing underlying disease at the 
onset of candidemia The low attributable mortality observed makes it even more difficult to 
explain the difference between survivors and non-survivors concerning the risk of hospital 
death at ICU admission (estimated by SAPS II) which was considerably higher in survivors In 
order to exclude concomitant bacterial sepsis which might have contributed to the non-
fungal-related mortality we evaluated the sequential occurrence of pathogens isolated from 
blood cultures 84% of the patients had primary candidemia or candidemia following 
bacteremia In both cases it might be assumed that the bacteremia did not contribute to 
the death of the patient which more likely was the case in those patients who suffered from 
simultaneous bacteremia (7%) or who's candidemia was followed by bacterial sepsis (9%) 
Risk factors for the development of candidemia were of no further value to predict mortality 
once candidemia has developed Other clinical conditions associated with impaired immunity 
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that may facilitate opportunistic infections, such as age, sex, gastrointestinal bleeding, 
pneumonia, diabetes mellitus, chronic obstructive pulmonary disease, steroid use, or prior 
alcohol abuse, did not significantly contribute to mortality in patients with candidemia. 
In recent years epidemiological changes of Candida infections have been documented by 
several authors indicating a shift toward (less azole-susceptible) non-C. albicans species 
especially in patients with AIDS and cancer 153242 whether or not these changes are due to the 
excessive use of fluconazole is debated in the literature, and would expand the spectrum of this 
discussion it2Ai. Overall, 75% of all blood culture isolates during the 8-year-study period were 
C. albicans. Until 1995, no patient with С (cruse/ candidemia was observed among ICU patients 
in our hospital 22°, and the proportion of other non-C. albicans species remained low. However, 
we demonstrated an upward trend during 1989 to 1993, and a steep increase of 97 
non-C. albicans species in 1994, when for the first time less than 50% of the Candida blood 
m 
culture isolates were C. albicans. s 
CD 3 
о 
о 
Frequently, ICU clinicians consider candidemia as an epi-phenomenon in already severely ill <§ 
о 
patients with a past history of bacterial sepsis. On the basis of our results candidemia should be Ζ 
considered as an independent variable for morbidity and mortality. Risk factors that might be j? 
helpful to predict the development of candidemia among non-neutropenic critically ill patients 
had no further value in predicting mortality among ICU patients with candidemia. The SAPS II
 а 
CL 
score taken at ICU admission was insufficient to indicate the actual risk of hospital death, since о 
the clinical outcome was primarily determined by the development of multiple organ dysfunc- ™ 
tion reflecting the severity of illness at the moment of candidemia | 
о 
Q 
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Chapter 5 
The increasing rate of fungal infections during the last d e c a d e most notably due to 
Candida species - is soundly documented in the Anglo-American literature Today Candida 
species are the most important fungal pathogens causing hospital-acquired infections and 
are recently among the top four nosocomial pathogens causing bloodstream infections in 
the US Given the increasing incidence high attributable mortality and increased health 
care costs associated with nosocomial candidemia many hospitals feel the pressing need for 
more and new effective preventive diagnostic and therapeutic measures to deal with this 
emerging group of pathogens Implicit in these issues is the need for an increased 
understanding of the epidemiology of systemic Candida infections Advances in the 
antifungal treatment and prophylaxis of Candida albicans infections may promote the % 
CQ 
emergence of other more resistant species The incidence and clinical significance of this • 
phenomenon especially in the growing non-immunocompromised patient population ~& 
CD 
needed to be surveyed Furthermore the reservoir and mode of transmission of exogenous i 
Candida infections should be assessed New molecular typing techniques are important Q 
tools in clinical and epidemiologic investigations to solve the above mentioned problems §; 
a 
These studies are essential to the rational development of effective measures to prevent and з 
m 
to control nosocomial infections caused by Candida species g-
In chapter 2 1 the usefulness of karyotypes established by contour-clamped homogenous 
electric field (CHEF) gel electrophoresis CHEF restriction fragment analysis (RFA) and 
isoenzyme profiles to investigate outbreaks was analyzed in a set of epidemiological^ related 
Candida tropicalis strains earlier characterized by conventional RFA Karyotyping by 
conventional CHEF gel electrophoresis was inadequate to delineate related and unrelated 
strains whereas CHEF RFA patterns allowed easy delineation However the limits to the 
discriminative power of this procedure were not fully explored 
An evaluation of PCR-fingerpnnting CHEF karyotyping and RFA in multiple reference strains 
from seven Candida species (chapter 2 2) made clear that despite recent progress to 
standardize and validate typing systems only insufficient discriminatory power is achieved in 
Cand/da species other than С albicans To fulfill recently published standards the available 
typing systems still need further improvement The ability to delineate Candida strains should 
be evaluated in a great number of unrelated strains (>20) and typing standards should 
include specific restriction enzymes or PCR primers validated on species level 
Nevertheless at the moment genomic DNA typing methods are the ones most appropriate 
for molecular epidemiology studies as those described in chapter 3 1 and 3 2 
101 
Ό 
a 
CD 
3 
Summary 
For α long time it was believed that Candida infections solely originated from the patient's 
own flora Proof of such endogenous infections in hospitalized patients was given by the 
findings that unique strains of Candida were seen for each patient, that colonizing and 
infecting strains usually shared the same DNA type, and that the colonizing isolate usually 
preceded the invasive isolate (chapter 3 1) Particularly in the ICU setting patient to patient 
transmission of Candida species was assumed to be of importance, next to the endogenous 
infections The use of two molecular typing methods suggested that some transmission may 
have occurred among patients of an ICU (chapter 3 2) Differences observed with a third 
typing approach may reflect the propensity for С albicans to undergo genomic 
rearrangements, but suggests that although these isolates may have had a common origin, 
102 direct patient-to-patient or health care worker-to-patient transmission was unlikely 
Recent data from the USA indicated major changes in the epidemiology of fungal infections, 
m 
^ including the increasing incidence of Candida bloodstream infections Chapter 4 1 
Φ 
3 describes the results of a retrospective multi-center study defining secular trends in yeast 
о 
со bloodstream infections in The Netherlands The candidemia rate found among Dutch 
-< 
2, university hospital patients (0 70 per 10,000 patient days in 1995) show the same trend 
-< 
j observed among patients in the USA, but on a much lower scale and with a less dramatic 
5 increase The trend of candidemias due to non-C albicans species parallels the one due to 
Q С albicans, the species that still causes 60% of all episodes of Candida bloodstream 
ä infections Q 
Despite it's relatively rare occurrence, candidemia poses a serious threat to 
immunocompromised and ICU patients in which it was shown to have the shortest survival 
prospects of any blood-borne infections In chapter 4 2 we tried to evaluate whether risk-
factors predicting the development of candidemia were of further value to predict patients 
who are most likely to die from the fungal infection With the exception of the multiple organ 
dysfunction syndrome reflecting the severity of illness at the moment of candidemia no 
further risk-factors hold through in a multi variant analysis 
Regarding the increasing incidence of invasive Candida infections and the unpredictability 
of its clinical outcome, future investigations should be aiming at improving prevention and 
treatment Especially the group of seriously ill non-neutropenic patients deserves more 
attention regarding further data on the epidemiology (carrier-ship and transmission) and the 
development of treatment strategies that might help to prevent a further shift to Candida 
species which are less-susceptible to presently available antifungals 
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Samenvatting 
De toenemende meidende van gist- en schimmelinfecties tijdens de laatste decennia - in het 
bijzonder door Candida soorten - is goed gedocumenteerd in de Anglo-Amerikaanse 
literatuur Hendentendage behoren Candida soorten tot de belangrijkste verwekkers van 
ziekenhuis-infecties en zijn de 4e in de rij van nosocomiale verwekkers die in de V S uit 
bloedkweken geïsoleerd worden Gezien de toenemende incidentie de hoge attributieve 
letahteit en de hoge kosten die geassocieerd zijn met nosocomiale candidemieen is het 
belangrijk voor de gezondheidszorg nieuwe effectieve maatregelen ter preventie 
diagnostiek en therapie van infecties door deze micro-organismen te ontwikkelen Om te 
komen tot een nationaal beleid ten aanzien van nosocomiale Candida infecties is het in 103 
kaart brengen van het probeem een eerste vereiste 
•g 
Vooraleerst is het noodzakelijk de epidemiologie van systemische Candida infecties beter te g· 
begrijpen Daarbij moet men een onderscheid maken tussen infecties door Candida albicans §. 
о 
en Candida niet-albicans Er zijn aanwijzingen dat er naast een toegenoemen incidentie in !< 
o 
het algemeen ook een shift ten gunste van de niet-albicans species waar te nemen is £ 
Het toenemende gebruik van antifungale therapie en profylaxe van Candida albicans ^ 
infecties zou voor het optreden van andere en resistentere Candida species verantwoordelijk <-> 
Û 
zijn Een surveillance van de incidentie en klinische significantie van dit fenomeen was o. 
а 
daarvoor noodzakelijk vooral in de groeiende groep van met-immuno-gecompromitteerde ° 
patiënten Ook de bron en de mogelijke transmissieweg van exogene Candida infecties o 
δ 
behoefde verder onderzoek 3 
In hoofdstuk 2 1 werd het nut van contour-clamped homogenous electric field (CHEF) 
karyotypering CHEF restrictie fragment analyse (RFA) en isoenzyme profielen voor het 
onderzoek van epidemieën geanalyseerd aan de hand van een set epidemiologisch 
gerelateerde Candida tropicalis stammen die eerder door middel van conventionele RFA 
gekarakteriseerd zijn Karyotypering middels conventionele CHEF gel electrophoresis bleek 
inadequaat om gerelateerde en niet gerelateerde stammen te differentieren Wel was dit 
met CHEF-RFA mogelijk maar het discriminerende vermogen van deze procedure was nog 
niet helemaal uitgezocht 
De evaluatie van PCR fingerprinting CHEF karyotypering en RFA m verschillende 
referentiestammen van 7 Candida species (hoofdstuk 2 2) maakte duidelijk dat ondanks 
recente verbeteringen om typeringssystemen te standaardiseren en te valideren het 
discriminerend vermogen van deze systemen met betrekking tot Candida species anders 
dan Candida albicans onvoldoende lijkt Om recent gepubliceerde standaarden te kunnen 
naleven moeten de huidige methoden nog verbeterd worden Het vermogen Candida 
stammen te differentieren zou in een groot aantal ongerelateerde isolaten (>20) 
geëvalueerd moeten worden Standaard с q normen met betrekking tot de typering van 
Summary 
gisten zouden informatie met betrekking tot species specifieke restrictie enzymen с q PCR 
primers moeten bevatten 
Desondanks zijn genomische DNA typeringsmethoden momenteel het meest geschikt voor 
moleculaire epidemiologische studies zoals die beschreven zijn in hoofdstuk 3 1 en 3 2 
Oorspronkelijk was men ervan uitgegaan dat Candida infecties uitsluitend door stammen 
van de patiënten zelf veroorzaakt werden (endogene infecties) Dit stoelde op de 
waarneming dat er voor iedere patient eigen" Candida stammen werden gevonden dat 
de koloniserende en infecterende stam meestal van een identiek DNA type was en dat het 
koloniserende isolaat meestal op een eerder tijdstip dan het mvasieve isolaat gevonden 
werd (hoofdstuk 3 1) BIJ mtensieve-zorg patiënten rees het vermoeden dat naast de 
104 endogene infectieweg ook een horizontale overdracht van Candida species van patient 
naar patient belangrijk zou kunnen zijn Het gebruik van twee moleculaire typenngs-
m 
^ methoden suggereerde dat een dergelijke transmissie onder intensieve zorg patiënten zeer 
Φ 
3 wel mogelijk was (hoofdstuk 3 2) Wel zijn bij gebruik van een derde typeringsmethode 
o (o verschillen tussen de stammen gevonden die laten vermoeden dat ook als het voor 
-< 
2, С albicans mogelijk zou zijn genomische veranderingen te ondergaan en daarmee de 
• < 
•2- bovengenoemde isolaten een gemeenschappelijke oorsprong hadden directe overdracht 
ñ van patient op patient of van gezondheidsmedewerker naar de patient onwaarschijnlijk was 
o 
o 
D 
o. Recente gegevens uit de VS toonden aan dat ingrijpende veranderingen in de 
o 
5 epidemiologie van gist infecties plaatsgevonden hebben waaronder ook een toenemende 
Φ 2. incidentie van candidemieen Hoofdstuk 4 1 beschrijft de resultaten van een retrospectieve 
o 
multicentnsche studie naar het voorkomen van candidemieen in Nederland over de tijd De 
incidentie van candidemieen bij patiënten van 5 academische ziekenhuizen (0 70 per 10 000 
patientendagen in 1995) laat dezelfde trend zien als gesignaleerd bij patiënten uit de V S 
maar op een lager niveau en met een minder duidelijke stijging De toename van 
candidemieen veroorzaakt door С niet-albicans species loopt parallel met die veroorzaakt 
door С albicans de soort die tot nu toe verantwoordelijk was voor 60% van alle 
candidemieen 
Hoewel candidemien zeldzaam zijn vormen zij een ernstige bedreiging voor immuno 
gecompromitteerde en mtensieve-zorg patiënten patiënten met een candidaemie hebben 
een lagere kans op overleving dan patiënten met sepsis door een andere verwekker In 
hoofdstuk 4 2 worden risicofactoren onderzocht die het mogelijk maken om het ontstaan van 
een candidemie te voorspellen en een verdere voorspellende waarde met betrekking tot de 
letaliteit van deze patiënten te stellen De ernst van het onderliggend lijden is de 
belangrijkste zelfs enige risicofactor voor het verkrijgen van een candidemie Dit werd fraai 
aangetoond bij patiënten met een multiple dysfuntion syndrome 
Gezien de toenemende incidentie van mvasieve Candida infecties en de 
onvoorspelbaarheid van het klinische beloop zou het onderzoek zich zeker ook op een 
Chapler 5 
verbetering van preventie en therapie moeten richten In het bijzonder bij ernstig zieke niet 
neutropene patiënten zouden meer gegevens verzameld moeten worden over 
epidemiologie (dragerschap en transmissie) Van evenzoveel belang is het ontwikkelen van 
therapeutische strategieën die een verdere shift naar Candida species die minder gevoelig 
zijn voor de huidige antimycotica, kunnen voorkomen 
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Zusammenfassung 
Die steigende Inzidenz von Pilzmfektionen wahrend des letzten Jahrzehntes insbesondere 
durch Candida Spezies ist in der anglo-/amenkanischen Literatur gut dokumentiert Heute 
sind Candida Spezies die wichtigsten Erreger von Krankenhaus-erworbenen Pilzmfektionen 
Sie gehören in den USA seit kurzem zu den vier häufigsten Sepsiserregern Angesichts der 
zunehmenden Inzidenz der hohen attributiven Mortalität und der steigenden Kosten die mit 
Krankenhaus-erworbenen Candidamien verbunden sind ist die Notwendigkeit entstanden 
nach neuen und effektiven Maßnahmen zur Prävention Diagnostik und Therapie dieser 
aktuellen Erreger zu suchen Voraussetzung hierfür ist eine verbesserte Einsicht in die 
Epidemiologie systemischer Candida Infektionen Eine Zunahme der antimykotischen ] 0 7 
Therapie und Prophylaxe von Candida albicans Infektionen kann zum Auftreten anderer
 m 
und/oder resistenterer Spezies fuhren Die Inzidenz und klinische Relevanz dieses Phänomens % 
3 
sollten ebenso wie mögliche Reservoirs und Ubertragungswege von Candida Infektionen о 
untersucht werden Molekulare Methoden zur Typisierung sind wichtige Mittel um deratige -< 
о 
klinische und epidemiologische Studien überhaupt zu ermöglichen Die Ergebnisse dieser % 
Studien bilden eine rationale Basis zur Entwicklung von effektiven Praventions- und 3 
ñ 
Kontrollmaßnahmen gegen Candida Infektionen о 
In Kapitel 2 1 wurde der Einsatz von contour clamped homogenous electric field (CHEF) g 
о 
Gelelektrophorese CHEF Restriktionsfragment Analyse (RFA) und Isoenzym Profilen zur
 3 
<t 
Aufklarung von Epidemien untersucht Benutzt wurden epidemiologisch zusammen- Q. 
о 
hangende Candida tropicalis Stamme die zu einem früheren Zeitpunkt bereits mittels 3 
konventioneller RFA typisiert worden waren Wahrend eine Unterscheidung in relatierde und 
unrelatierte Stamme mittels CHEF Karyotypierung nicht möglich war gelang dies anhand der 
CHEF-RFA Banden Zum Zeitpunkt der Untersuchung waren die diskriminierenden 
Eigenschaften dieser Methoden noch nicht vollständig explonert 
Die diskriminierenden Eigenschaften von PCR-fingerpnnting CHEF Karyotypierung und RFA 
wurden an Referenzstammen von sieben Candida Spezies ausgewertet Trotz aktueller 
Verbesserungen in der Standardisierbarkeit und Validierung der Typisierungsmethoden 
zeigten sich Mangel bei den sogenannten nicht С albicans Spezies Um entsprechend einer 
vor kurzem publizierten Norm arbeiten zu können mussen die im Moment verfugbaren 
Methoden verbessert werden Die Methode sollte in der Lage sein innerhalb der 
verschiedenster Candida Spezies eine grossere Anzahl (>20) nicht-relatierter Stamme zu 
unterscheiden Auch sollten Normen explizit Restriktionsenzyme und PCR primers 
beschreiben die auf Speziesniveau validiert wurden 
Trotzdem sind die Gentypisierungen zur Zeit die besten Methoden die uns fur molekular-
epidemiologische Studien (wie in Kapitel 3 1 und 3 2 beschrieben) zur Verfugung stehen 
Summary 
Relativ lange war man der Ansicht, daß Candida Infektionen ausschließlich von der 
patienteneigenen Flora ausgehen Daß bei jedem hospitalisierten Patienten individuelle 
Candida Stamme gefunden wurden, daß kolonisierende und infizierende Stämme meistens 
den gleichen DNA-Typ aufwiesen und daß überwiegend erst eine Kolonisation und danach 
eine Infektion erfogte, waren weitere Hinweise für diesen endogenen Infektionsweg (Kapitel 
3 1). Vor allem bei Intensivpatienten wurde jedoch vermutet, daß es auch zu Kreuz-
infektionen mit Candida kommen kann Mittels zweier molekularer Typisierungstechniken 
haben wir solche Kreuzinfektionen bei Intensivpatienten nachgewiesen (Kapitel 3.2). Die 
mittels einer dritten Methode gefundenen Unterschiede könnten durch kleine genetische 
Veränderungen der Candida Isolate zustande gekommem sein, lassen aber auch die 
Annahme zu, daß - trotz eines möglichen gemeinsamen Ursprungs - in der beschriebenen 
m Situation keine Kreuzinfektion stattgefunden hat 
Φ Aktuelle Daten aus den USA zeigen erhebliche Veränderungen in der Epidemiologie 
ö mykotischer Erkrankungen inklusiv einer Zunahme der Inzidenz von Candidämien. Kapitel 4.1 
•< gibt die Ergebnisse einer niederländischen multi-zenter Studie wieder. Der Trend von 
о 
Ц Candidante unter niederländischen Patienten (Inzidenz 0,70 per 10.000 Patiententagen) war 
2 vergleichbar dem unter US Patienten, aber auf einem niedrigeren Niveau bei deutlich 
" weniger steilem Anstieg. Die Trendkurven der durch C. albicans und nicht-C. albicans 
Q 
3 verursachten Septikämien verliefen parallel. Auch 1995 war C. albicans noch der häufigste 
о Verursacher von Candidämien (60%). 
5 
Φ Trotz des geringen Vorkommens stellen Candidämien eine ernste Bedrohung dar, besonders 
g bei abwehrgeschwächten Patienten und bei Patienten der Intensivstation. Candida 
Septikämien weisen in diesen Patientengruppen eine höheren Letalität auf als Septikämien, 
die durch andere Mikroorganismen hervorgerufen werden. In Kapitel 4.2 wurde versucht zu 
klären, ob Risikofaktoren, die zur Entstehung einer Candidämie beitragen, auch Einfluß auf die 
Mortalität der Patienten haben. Mit Ausnahme des multiplen Organversagens, das den Ernst 
der Erkrankung zum Zeitpunkt der Candidämie wiederspiegelt, erwies sich keiner der 
untersuchten Risikofaktoren in der Multivarianz Analyse als signifikant. 
Im Hinblick auf die zunehmenden Inzidenz von invasiven Candida Infektionen und der 
Unvorhersagbarkeit des klinischen Verlaufs, sollten zukünftige Studien darauf gerichtet sein, 
Maßnahmen der Prävention und Therapie zu verbessern. Besonders im Hinblick auf die 
Gruppe der schwersterkrankten, nicht-neutropenen Patienten auf den Intensivstationen ist 
vermehrte Aufmerksamkeit im Bezug auf die Erhebung von epidemiologischen Daten zur 
Candía Trägerschaft und Übertragung erforderlich. Notwendig ist ebenfalls die Entwicklung 
von Therapieformen, die einen weiteren Shift zu Candida Spezies mit geringer Empfindlichkeit 
gegenüber den zur Zeit verfügbaren Antimykotika verhindern. 
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Stellingen 
behorend bij het proefschrift 
Epidemiology of systemic Candida infections: 
Studies to pursue the molecular and clinical epidemiology. 
Nijmegen, 13 juni 1997 
Andreas Voss 
Slellingen 
1. Even with the use of modern DNA-based typing methods, the classical 
epidemiological investigation is still the corner stone, since a single chromosomal 
deletion or insertion event (eg. acquisition or loss of bacteriophage) may result in 
different banding patterns. 
2. Discrimination between coincidental but independent infection and epidemics 
caused by a single isolate is a major concern that directly affects the preventive 
and hygienic measures to be taken (A. van Belkum, Clin Microbiol Rev, April 
1994). 
3. It is not only the biased observation of an eager scientist looking for new 
research opportunities that systemic fungal infections are rising and gaining 
clinical importance. 
4. Fungi Imperfecti can't have sex - therefore they attack man (M. Rinaldi, San 
Franciso 1995) 
5. One of the most important breakthroughs of the 19,h century was that physicians 
learned to wash their hands (von Bergmann, 1876). One of the most important 
breakthroughs of the 20th century could be that physicians remembered what 
they learned a century ago. 
6. You can get to see other people, sleep in peace, off-load decisions, feel 
important, and impress (or bore) your colleagues - and all in work time: " 
Meetings" the practical alternative to work. 
7. Diet Coke® is proven to be fattening! Significantly more Diet Coke® drinkers are 
overweight than Classic Coke® consumers (own experience and observation). 
8. Op de ICs van alle ziekenhuizen zou een teken moeten staan: " Handen wassen 
verboden". Misschien leert men dan uiteindelijk dat handen bijna altijd 
gedesinfecteerd moeten worden. (C. Vandenbroucke-Grauls, 1996) 
Stellingen 
9. Dat in veel instellingen de formatie van hygiënisten nog niet aan de GHI norm is 
aan gepast, berust op het feit dat ziekenhuisbestuurders twee normen kennen: 
"wettelijke" normen die direct kosten besparen (b.v. minder ruimte tussen 1С 
bedden) en "nieuwe te onderbouwen" normen die (in eerste instantie) kosten 
veroorzaken (b.v. tenminste 1 hygiënist per 250 bedden) 
10. Dank aan de Nederlandse Taalunie! De introduktie van de nieuwe spelling heeft 
het gat tussen mijn taalniveau en dat van de gemiddelde Nederlander kleiner 
gemaakt. 
11. Dat medici ondanks E. coli 0157, BSE, VRE en andere micro-organismen nog 
vlees eten moet iets met de natuurlijke ontkenning van doktoren met betrekking 
tot de eigen gezondheid te maken hebben ("The Swan with two Nicks" , Little 
Bullington, Cheshire, UK) 
12. Insofern ein vereintes Europa in der Zukunft eine gemeinsame Sprache sucht 
stimme ich für ein Gemisch aus Niederländisch, Deutsch und Englisch (= 
"Nledeutllsch", sprich: nie-deut-Uch), eine Sprache die ich schon jetzt perfekt 
beherrsche. 
13. " Ein Mann ohne Bauch ¡st ein Krüppel" (Chinese gids, Beijing - Verboden Stad, 
juni 1996) 
Stellingen 
De publikatie v a n dit proefschrift k w a m tot stand m e d e dankzij d e steun v a n : 
Janssen-Cilag в , Bartlett/Pfizer в , GlaxoWellcome BV. Leo Pharmaceutical Products BV, 
en: 
Abbott Bv, Bayer в , Eli Lilly Nederland в , Merck Sharp & Dohme в , Nexstar Pharmaceuticals 
BV, Roche Nederland BV, SmithKline Beecham BV, Schülke & Mayr Benelux BV 
Slellmgen 

Í,.GCL*U 
tàpr 
ш 
Ж 
ï&Q-i 
Lé&y 
Tí*, 
1
 - . • > ' 
ri . /-
шти 
> . • 
~ЛАГ№ рЛім^сОуУгиУПЛЛсО.^ ЛЬЛ-АН AVÉ r*jXt 
ІАЪ-
^hUübü, 
Ы°ешЬ%і. 
Ι ,лас« 
toer}, 
••'•;<: 
л , · . - i * , * 
_сх_ 
.'•&: Λ 
